Date: September 25, 2025

To
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400051, Maharashtra.

SYMBOL: QMSMEDI

Sub.: Rights Issue of Equity Shares of QMS Medical Allied Services Limited (the "Company or Issuer").

ISSUE OF UPTO 14,87,500 EQUITY SHARES OF FACE VALUE OF ₹10.00/- (RIGHTS EQUITY SHARES) OF QMS MEDICAL ALLIED SERVICES LIMITED (THE COMPANY OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 81/- (RUPEES EIGHTY-ONE ONLY) PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹71/- (RUPEES SEVENTY-ONE ONLY) PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") FOR AN AMOUNT TO ₹12,04,87,500/- (RUPEES TWELVE CRORE FOUR LAKH EIGHTY-SEVEN THOUSAND AND FIVE HUNDRED ONLY) ON A RIGHTS ISSUE BASIS TO THE ELIGIBLE SHAREHOLDERS IN THE RATIO OF ONE RIGHT SHARES FOR EVERY TWELVE EQUITY SHARES HELD BY SUCH ELIGIBLE SHAREHOLDERS AS ON THE RECORD DATE, SEPTEMBER 04, 2025 ("ISSUE").

With respect to the Issue, this is to confirm that in accordance with the applicable regulations of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations"), the Company has issued the following public announcement:

Announcement as per Regulation 92(1) of SEBI ICDR Regulations, (the "Post-Issue Advertisement") dated September 24, 2025 and published on September 25, 2025, giving details relating to subscription, basis of allotment, number, value and percentage of all applications including ASBA, number, value and percentage of successful allottees for all applications including ASBA, date of completion of dispatch of refund orders, as applicable, or instructions to self - certified syndicate banks by the Registrar, date of dispatch of certificates or date of credit of specified securities, as applicable, and date of filing of listing application, etc.

The Post-Issue Advertisement was published in the following newspapers:

Sr.No	Name of Newspaper(s)	Language	Editions
1.	Financial Express	English	All Editions
2.	Janasatta	Hindi	All Editions

QMS Medical Allied Services Ltd.
1A-1B / 2A-2B, Navkala Bharati Building, Plot No. 16, Prabhat Colony, Road No. 3, Santacruz (East), Mumbai - 400 055.
+91-022 - 6288 1111 www.qmsmas.com

CIN: L33309MH2017PLC299748; Email Id: mm@qmsmas.com

3.	Mumbai Lakshadeep	Marathi	Regional

In relation to the aforementioned, please find enclosed copy of the Post-Issue Advertisement dated September 24, 2025 and published on September 25, 2025 in the above mentioned newspapers.

All capitalised terms used in this letter and not defined shall have the meaning assigned to such terms in the Letter of Offer.

We request you to take the above on record and trust that the same is in order.

For QMS MEDICAL ALLIED SERVICES LIMITED

TORAL JAILESH BHADRA

Digitally signed by TORAL JAILESH BHADRA
Date: 2025.09.25 20:04:41 +05'30'

Toral Jailesh Bhadra
(Membership Number: A56927)
(Company Secretary and Compliance Officer)
Place: Mumbai

(This is only an Advertisement for information purpose and not an offer document announcement. Not for publication, distribution or release directly or indirectly into the United States or otherwise outside India.
All capitalized terms used and not defined herein shall have the meaning assigned to them in Letter of Offer dated August 29, 2025 ("the Letter of Offer" or "LOF") filed with National Stock Exchange of India and the Securities and Exchange Board of India ("SEBI").

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

QMS MEDICAL ALLIED SERVICES LIMITED ("Company" or "Issuer") was incorporated as a private limited company under the Companies Act, 2013 in the name of QMS MEDICAL ALLIED SERVICES PRIVATE LIMITED at Mumbai vide Certificate of Incorporation dated September 14, 2017. Pursuant to conversion of our Company to a public limited company, our name was changed to QMS MEDICAL ALLIED SERVICES LIMITED and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC, Mumbai on November 16, 2020. For details, please refer to the section titled "General Information" beginning on page no. 35 of the Letter of Offer.

Registered Office: AT A1 A2/B1 B2, NAVKALA BHARTI BLDG PLOT NO16 PRABHAT COLONY OPP NEAR SANTACRUZ BUS DEPOT SANTACRUZ EAST, MUMBAI CITY, MUMBAI, MAHARASHTRA, INDIA, 400055
Tel: +91 22 6288 1111 ; Contact Person: Ms. Toral Jailesh Bhadra, Company Secretary and Compliance Officer ;,
E-mail: contact@qmsmas.com; Website: www.qmsmas.com ; Corporate Identification Number: L33309MH2017PLC299748

PROMOTER OF OUR COMPANY: MAHESH MAKHIJA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF QMS MEDICAL ALLIED SERVICES LIMITED (THE "COMPANY" OR "THE ISSUER" ONLY

ISSUE OF 14,87,500 EQUITY SHARES OF FACE VALUE OF Rs. 10.00/- (RIGHTS EQUITY SHARES) OF QMS MEDICAL ALLIED SERVICES LIMITED (THE COMPANY OR THE "ISSUER") FOR CASH AT A PRICE OF Rs. 81/- (RUPEES EIGHTY-ONE ONLY) PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF Rs. 71/- (RUPEES SEVENTY-ONE ONLY) PER RIGHTS EQUITY SHARE) („ISSUE PRICE) FOR AN AMOUNT TO Rs. 12,04,87,500/- (RUPEES TWELVE CRORE FOUR LAKH EIGHTY-SEVEN THOUSAND AND FIVE HUNDRED ONLY) ON A RIGHTS ISSUE BASIS TO THE ELIGIBLE SHAREHOLDERS IN THE RATIO OF ONE RIGHT SHARES FOR EVERY TWELVE EQUITY SHARES HELD BY SUCH ELIGIBLE SHAREHOLDERS AS ON THE RECORD DATE, SEPTEMBER 04, 2025 ("ISSUE").

BASIS OF ALLOTMENT

The Board of Directors of QMS MEDICAL ALLIED SERVICES LIMITED wishes to thank all its members and investors for the overwhelming response to the Company's Rights Issue of Equity Shares, which opened for subscription on Friday, September 12, 2025 and closed on Monday, September 22, 2025 and the last date for market renunciation of Rights Entitlements was on Wednesday, September 17, 2025. In Rights Issue we received total 529 Applications for 22,02,820 Equity Shares (includes 4 applications of 10,71,613 Equity shares by Specific Investor) through Application Supported by Blocked Amount ("ASBA"). Applications for 78767 Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The application for 5 cases having 12,118 Additional Rights Equity Shares were rejected where the shareholder had partly renounced and applied for Additional Rights Equity Shares. The said Applications for 12,118 Additional Rights Equity Shares have not been considered for Allotment. The total number of valid applications received were 296 for 21,24,053 Equity Shares, which aggregates to 142.79% of the total number of Equity Shares allotted under the Issue. In accordance with the LOF the basis of allotment finalized on Tuesday, September 23, 2025 in consultation with the Company, the Registrar to the Issue and National Stock Exchange of India Limited, the Stock Exchange for the Issue. The Company has on Tuesday, September 23, 2025 allotted 14,87,443 Rights Equity Shares to the successful applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. We hereby confirm that all the valid applications have been considered for Allotment.
In accordance with Regulation 86 of SEBI ICDR Regulations, 2018 Our Company is required to achieve minimum subscription for the Rights Issue.

1.Information regarding total number of Applications received:

Category	Applications Received		Equity Shares Applied for			Equity Shares allotted		
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%
Eligible Equity Shareholders	503	95.09 %	9,33,833	7,56,40,473	42.39 %	3,66,196	2,96,61,876	24.62%
Renouncees	22	4.16 %	1,96,295	1,58,99,895	8.91 %	49,551	40,13,631	3.33 %
Specific Investor*	4	0.76 %	10,72,692	8,68,88,052	48.70 %	10,71,696	8,68,07,376	72.05 %
Total	**529**	**100.00%**	**22,02,820**	**17,84,28,420**	**100.00 %**	**14,87,443**	**12,04,82,883**	**100.00 %**

*** In terms of Reg 77B (1) (a)** of SEBI ICDR Regulations, 2018, the Company had published a public advertisement in the newspaper specifying the name of Specific Investor,
The details of Specific Investor from whom applications were received are as mentioned below:

Sr. No	Name of Specific Investor	Equity Shares allotted	Value (Rs)
1	AMRIT KAAL OPPORTUNITIES FUND	3,09,922	2,51,03,682
2	Mr. ASHSISH VASANI	61,918	50,15,358
3	Mr. GUARANG VASANI ON BEHALF OF M/S. STELLAR GROWTH ADVISORS	6,36,693	5,15,72,133
4	Ms. VRANDA RATHI	63,163	51,16,203

2.Basis of Allotment

Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)
	Number	Number	Number	Number
Shareholders	270	2,13,974	1,52,222	3,66,196
Renouncees	22	49,551	0	49,551
Specific Investor	4	10,71,613	83	10,71,696
Total	**296**	**13,35,138**	**1,52,305**	**14,87,443**

Intimations for Allotment/refund/rejection cases: The dispatch of allotment advice cum refund intimation, as applicable, to the investors has been completed on September 24, 2025.The instructions to SCSBs for unblocking funds in case of ASBA Applications were given on September 23, 2025. The Listing application has been filed with NSE on September 24, 2025 and subsequently the Listing approval will be received on or about September 25, 2025. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of allottees will be completed on or about September 25, 2025. No Physical shares were tendered in the Rights Issue. Pursuant to Listing and Trading Approvals granted by National Stock Exchange of India Limited, the Rights Equity Shares Allotted in the issue is expected to commence the trading on National Stock Exchange of India Limited on or about September 26, 2025 and shall be traded under the same ISIN: INE0FMW01018 as the existing Equity Shares. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has be sent to NSDL & CDSL on or about Wednesday, September 24, 2025.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM

DISCLAIMER CLAUSE OF NSE (STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not, in any way, be deemed or construed that the Letter of Offer has been cleared or approved by the NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer in the full text of the "Disclaimer clause of NSE" on page 59 of the Letter of Offer.
Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

REGISTRAR TO THE ISSUE	Company Secretary
Bigshare Services Private Limited **1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400 059, Maharashtra, India.** **Tel No.: +91 22 6263 8200** **Email: rightsissue@bigshareonline.com** **Website:** www.bigshareonline.com **Investor Grievance Email:** investor@bigshareonline.com **Contact Person: Mr. Suraj Gupta** **SEBI Registration No.: INR000001385** **Validity of Registration: Permanent**	**Toral Jailesh Bhadra** A1 A2/B1 B2, Navkala Bharti Bldg , Plot No16 Prabhat Colony, opp near Santacruz Bus depot Santacruz East, Mumbai City, Mumbai, Maharashtra, India, 400055. **Telephone:** +91 22 6288 1111 **Email**: contact@qmsmas.com **Website:** : www.qmsmas.com

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving folio details such as name, address of the Applicant contact numbers), e- mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process) ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as the-case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process).

THE LEVEL OF SUBSCRPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

FOR QMS MEDICAL ALLIED SERVIES Limited
Sd/-
Toral Jailesh Bhadra
Company Secretary & Compliance Officer

Date: September 24, 2025
Place: Mumbai

Disclaimer: The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. NSE at www.nseindia.com and the website of the Registrar to the issue at bigshareonline.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 22 of the Letter of Offer.

(This is only an Advertisement for information purpose and not an offer document announcement. Not for publication, distribution or release directly or indirectly into the United States or otherwise outside India.
All capitalized terms used and not defined herein shall have the meaning assigned to them in Letter of Offer dated August 29, 2025 ("the Letter of Offer" or "LOF") filed with National Stock Exchange of India and the Securities and Exchange Board of India ("SEBI").

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

QMS MEDICAL ALLIED SERVICES LIMITED ("Company" or "Issuer") was incorporated as a private limited company under the Companies Act, 2013 in the name of QMS MEDICAL ALLIED SERVICES PRIVATE LIMITED at Mumbai vide Certificate of Incorporation dated September 14, 2017. Pursuant to conversion of our Company to a public limited company, our name was changed to QMS MEDICAL ALLIED SERVICES LIMITED and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC, Mumbai on November 16, 2020. For details, please refer to the section titled "General Information" beginning on page no. 35 of the Letter of Offer.

Registered Office: AT A1 A2/B1 B2, NAVKALA BHARTI BLDG PLOT NO16 PRABHAT COLONY OPP NEAR SANTACRUZ BUS DEPOT SANTACRUZ EAST, MUMBAI CITY, MUMBAI, MAHARASHTRA, INDIA, 400055
Tel: +91 22 6288 1111 ; Contact Person: Ms. Toral Jailesh Bhadra, Company Secretary and Compliance Officer ;,
E-mail: contact@qmsmas.com; Website: www.qmsmas.com ; Corporate Identification Number: L33309MH2017PLC299748

PROMOTER OF OUR COMPANY: MAHESH MAKHIJA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF QMS MEDICAL ALLIED SERVICES LIMITED (THE "COMPANY" OR "THE ISSUER" ONLY

ISSUE OF 14,87,500 EQUITY SHARES OF FACE VALUE OF Rs. 10.00/- (RIGHTS EQUITY SHARES) OF QMS MEDICAL ALLIED SERVICES LIMITED (THE COMPANY OR THE "ISSUER") FOR CASH AT A PRICE OF Rs. 81/- (RUPEES EIGHTY-ONE ONLY) PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF Rs. 71/- (RUPEES SEVENTY-ONE ONLY) PER RIGHTS EQUITY SHARE) („ISSUE PRICE) FOR AN AMOUNT TO Rs. 12,04,87,500/- (RUPEES TWELVE CRORE FOUR LAKH EIGHTY-SEVEN THOUSAND AND FIVE HUNDRED ONLY) ON A RIGHTS ISSUE BASIS TO THE ELIGIBLE SHAREHOLDERS IN THE RATIO OF ONE RIGHT SHARES FOR EVERY TWELVE EQUITY SHARES HELD BY SUCH ELIGIBLE SHAREHOLDERS AS ON THE RECORD DATE, SEPTEMBER 04, 2025 ("ISSUE").

BASIS OF ALLOTMENT

The Board of Directors of QMS MEDICAL ALLIED SERVICES LIMITED wishes to thank all its members and investors for the overwhelming response to the Company's Rights Issue of Equity Shares, which opened for subscription on Friday, September 12, 2025 and closed on Monday, September 22, 2025 and the last date for market renunciation of Rights Entitlements was on Wednesday, September 17, 2025. In Rights Issue we received total 529 Applications for 22,02,820 Equity Shares (includes 4 applications of 10,71,613 Equity shares by Specific Investor) through Application Supported by Blocked Amount ("ASBA"). Applications for 78767 Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The application for 5 cases having 12,118 Additional Rights Equity Shares were rejected where the shareholder had partly renounced and applied for Additional Rights Equity Shares. The said Applications for 12,118 Additional Rights Equity Shares have not been considered for Allotment. The total number of valid applications received were 296 for 21,24,053 Equity Shares, which aggregates to 142.79% of the total number of Equity Shares allotted under the Issue. In accordance with the LOF the basis of allotment finalized on Tuesday, September 23, 2025 in consultation with the Company, the Registrar to the Issue and National Stock Exchange of India Limited, the Stock Exchange for the Issue. The Company has on Tuesday, September 23, 2025 allotted 14,87,443 Rights Equity Shares to the successful applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. We hereby confirm that all the valid applications have been considered for Allotment.
In accordance with Regulation 86 of SEBI ICDR Regulations, 2018 Our Company is required to achieve minimum subscription for the Rights Issue.

1.Information regarding total number of Applications received:

Category	Applications Received		Equity Shares Applied for			Equity Shares allotted		
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%
Eligible Equity Shareholders	503	95.09 %	9,33,833	7,56,40,473	42.39 %	3,66,196	2,96,61,876	24.62%
Renouncees	22	4.16 %	1,96,295	1,58,99,895	8.91 %	49,551	40,13,631	3.33 %
Specific Investor*	4	0.76 %	10,72,692	8,68,88,052	48.70 %	10,71,696	8,68,07,376	72.05 %
Total	**529**	**100.00%**	**22,02,820**	**17,84,28,420**	**100.00 %**	**14,87,443**	**12,04,82,883**	**100.00 %**

*** In terms of Reg 77B (1) (a)** of SEBI ICDR Regulations, 2018, the Company had published a public advertisement in the newspaper specifying the name of Specific Investor,
The details of Specific Investor from whom applications were received are as mentioned below:

Sr. No	Name of Specific Investor	Equity Shares allotted	Value (Rs)
1	AMRIT KAAL OPPORTUNITIES FUND	3,09,922	2,51,03,682
2	Mr. ASHSISH VASANI	61,918	50,15,358
3	Mr. GUARANG VASANI ON BEHALF OF M/S. STELLAR GROWTH ADVISORS	6,36,693	5,15,72,133
4	Ms. VRANDA RATHI	63,163	51,16,203

2.Basis of Allotment

Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)
	Number	Number	Number	Number
Shareholders	270	2,13,974	1,52,222	3,66,196
Renouncees	22	49,551	0	49,551
Specific Investor	4	10,71,613	83	10,71,696
Total	**296**	**13,35,138**	**1,52,305**	**14,87,443**

Intimations for Allotment/refund/rejection cases: The dispatch of allotment advice cum refund intimation, as applicable, to the investors has been completed on September 24, 2025.The instructions to SCSBs for unblocking funds in case of ASBA Applications were given on September 23, 2025. The Listing application has been filed with NSE on September 24, 2025 and subsequently the Listing approval will be received on or about September 25, 2025. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of allottees will be completed on or about September 25, 2025. No Physical shares were tendered in the Rights Issue. Pursuant to Listing and Trading Approvals granted by National Stock Exchange of India Limited, the Rights Equity Shares Allotted in the issue is expected to commence the trading on National Stock Exchange of India Limited on or about September 26, 2025 and shall be traded under the same ISIN: INE0FMW01018 as the existing Equity Shares. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has be sent to NSDL & CDSL on or about Wednesday, September 24, 2025.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM

DISCLAIMER CLAUSE OF NSE (STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not, in any way, be deemed or construed that the Letter of Offer has been cleared or approved by the NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer in the full text of the "Disclaimer clause of NSE" on page 59 of the Letter of Offer.

Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

REGISTRAR TO THE ISSUE	Company Secretary
Bigshare Services Private Limited 1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400 059, Maharashtra, India. Tel No.: +91 22 6263 8200 Email: rightsissue@bigshareonline.com Website: www.bigshareonline.com Investor Grievance Email: investor@bigshareonline.com Contact Person: Mr. Suraj Gupta SEBI Registration No.: INR000001385 Validity of Registration: Permanent	**Toral Jailesh Bhadra** A1 A2/B1 B2, Navkala Bharti Bldg , Plot No16 Prabhat Colony, opp near Santacruz Bus depot Santacruz East, Mumbai City, Mumbai, Maharashtra, India, 400055. **Telephone:** +91 22 6288 1111 **Email**: contact@qmsmas.com **Website:** : www.qmsmas.com

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving folio details such as name, address of the Applicant contact numbers), e- mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process) ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as the-case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process).

THE LEVEL OF SUBSCRPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

FOR QMS MEDICAL ALLIED SERVIES Limited
Sd/-
Toral Jailesh Bhadra
Company Secretary & Compliance Officer

Date: September 24, 2025
Place: Mumbai

Disclaimer: The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. NSE at www.nseindia.com and the website of the Registrar to the issue at bigshareonline.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 22 of the Letter of Offer.

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

QMS MEDICAL ALLIED SERVICES LIMITED ("Company" or "Issuer") was incorporated as a private limited company under the Companies Act, 2013 in the name of QMS MEDICAL ALLIED SERVICES PRIVATE LIMITED at Mumbai vide Certificate of Incorporation dated September 14, 2017. Pursuant to conversion of our Company to a public limited company, our name was changed to QMS MEDICAL ALLIED SERVICES LIMITED and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC, Mumbai on November 16, 2020. For details, please refer to the section titled "General Information" beginning on page no. 35 of the Letter of Offer.

Registered Office: AT A1 A2/B1 B2, NAVKALA BHARTI BLDG PLOT NO16 PRABHAT COLONY OPP NEAR SANTACRUZ BUS DEPOT SANTACRUZ EAST, MUMBAI CITY, MUMBAI, MAHARASHTRA, INDIA, 400055
Tel: +91 22 6288 1111 ; Contact Person: Ms. Toral Jailesh Bhadra, Company Secretary and Compliance Officer ;,
E-mail: contact@qmsmas.com; Website: www.qmsmas.com ; Corporate Identification Number: L33309MH2017PLC299748

PROMOTER OF OUR COMPANY: MAHESH MAKHIJA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF QMS MEDICAL ALLIED SERVICES LIMITED (THE "COMPANY" OR "THE ISSUER" ONLY

ISSUE OF 14,87,500 EQUITY SHARES OF FACE VALUE OF Rs. 10.00/- (RIGHTS EQUITY SHARES) OF QMS MEDICAL ALLIED SERVICES LIMITED (THE COMPANY OR THE "ISSUER") FOR CASH AT A PRICE OF Rs. 81/- (RUPEES EIGHTY-ONE ONLY) PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF Rs. 71/- (RUPEES SEVENTY-ONE ONLY) PER RIGHTS EQUITY SHARE) („ISSUE PRICE) FOR AN AMOUNT TO Rs. 12,04,87,500/- (RUPEES TWELVE CRORE FOUR LAKH EIGHTY-SEVEN THOUSAND AND FIVE HUNDRED ONLY) ON A RIGHTS ISSUE BASIS TO THE ELIGIBLE SHAREHOLDERS IN THE RATIO OF ONE RIGHT SHARES FOR EVERY TWELVE EQUITY SHARES HELD BY SUCH ELIGIBLE SHAREHOLDERS AS ON THE RECORD DATE, SEPTEMBER 04, 2025 ("ISSUE").

BASIS OF ALLOTMENT

The Board of Directors of QMS MEDICAL ALLIED SERVICES LIMITED wishes to thank all its members and investors for the overwhelming response to the Company's Rights Issue of Equity Shares, which opened for subscription on Friday, September 12, 2025 and closed on Monday, September 22, 2025 and the last date for market renunciation of Rights Entitlements was on Wednesday, September 17, 2025. In Rights Issue we received total 529 Applications for 22,02,820 Equity Shares (includes 4 applications of 10,71,613 Equity shares by Specific Investor) through Application Supported by Blocked Amount ("ASBA"). Applications for 78767 Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The application for 5 cases having 12,118 Additional Rights Equity Shares were rejected where the shareholder had partly renounced and applied for Additional Rights Equity Shares. The said Applications for 12,118 Additional Rights Equity Shares have not been considered for Allotment. The total number of valid applications received were 296 for 21,24,053 Equity Shares, which aggregates to 142.79% of the total number of Equity Shares allotted under the Issue. In accordance with the LOF the basis of allotment finalized on Tuesday, September 23, 2025 in consultation with the Company, the Registrar to the Issue and National Stock Exchange of India Limited, the Stock Exchange for the Issue. The Company has on Tuesday, September 23, 2025 allotted 14,87,443 Rights Equity Shares to the successful applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. We hereby confirm that all the valid applications have been considered for Allotment.
In accordance with Regulation 86 of SEBI ICDR Regulations, 2018 Our Company is required to achieve minimum subscription for the Rights Issue.

1.Information regarding total number of Applications received:

Category	Applications Received		Equity Shares Applied for			Equity Shares allotted		
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%
Eligible Equity Shareholders	503	95.09 %	9,33,833	7,56,40,473	42.39 %	3,66,196	2,96,61,876	24.62%
Renouncees	22	4.16 %	1,96,295	1,58,99,895	8.91 %	49,551	40,13,631	3.33 %
Specific Investor*	4	0.76 %	10,72,692	8,68,88,052	48.70 %	10,71,696	8,68,07,376	72.05 %
Total	**529**	**100.00%**	**22,02,820**	**17,84,28,420**	**100.00 %**	**14,87,443**	**12,04,82,883**	**100.00 %**

*** In terms of Reg 77B (1) (a)** of SEBI ICDR Regulations, 2018, the Company had published a public advertisement in the newspaper specifying the name of Specific Investor,
The details of Specific Investor from whom applications were received are as mentioned below:

Sr. No	Name of Specific Investor	Equity Shares allotted	Value (Rs)
1	AMRIT KAAL OPPORTUNITIES FUND	3,09,922	2,51,03,682
2	Mr. ASHSISH VASANI	61,918	50,15,358
3	Mr. GUARANG VASANI ON BEHALF OF M/S. STELLAR GROWTH ADVISORS	6,36,693	5,15,72,133
4	Ms. VRANDA RATHI	63,163	51,16,203

2.Basis of Allotment

Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)
	Number	Number	Number	Number
Shareholders	270	2,13,974	1,52,222	3,66,196
Renouncees	22	49,551	0	49,551
Specific Investor	4	10,71,613	83	10,71,696
Total	**296**	**13,35,138**	**1,52,305**	**14,87,443**

Intimations for Allotment/refund/rejection cases: The dispatch of allotment advice cum refund intimation, as applicable, to the investors has been completed on September 24, 2025.The instructions to SCSBs for unblocking funds in case of ASBA Applications were given on September 23, 2025. The Listing application has been filed with NSE on September 24, 2025 and subsequently the Listing approval will be received on or about September 25, 2025. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of allottees will be completed on or about September 25, 2025. No Physical shares were tendered in the Rights Issue. Pursuant to Listing and Trading Approvals granted by National Stock Exchange of India Limited, the Rights Equity Shares Allotted in the issue is expected to commence the trading on National Stock Exchange of India Limited on or about September 26, 2025 and shall be traded under the same ISIN: INE0FMW01018 as the existing Equity Shares. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has be sent to NSDL & CDSL on or about Wednesday, September 24, 2025.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM

DISCLAIMER CLAUSE OF NSE (STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not, in any way, be deemed or construed that the Letter of Offer has been cleared or approved by the NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer in the full text of the "Disclaimer clause of NSE" on page 59 of the Letter of Offer.

Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

REGISTRAR TO THE ISSUE	Company Secretary
Bigshare Services Private Limited **1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400 059, Maharashtra, India.** **Tel No.: +91 22 6263 8200** **Email: rightsissue@bigshareonline.com** **Website:** www.bigshareonline.com **Investor Grievance Email:** investor@bigshareonline.com **Contact Person: Mr. Suraj Gupta** **SEBI Registration No.: INR000001385** **Validity of Registration: Permanent**	**Toral Jailesh Bhadra** A1 A2/B1 B2, Navkala Bharti Bldg , Plot No16 Prabhat Colony, opp near Santacruz Bus depot Santacruz East, Mumbai City, Mumbai, Maharashtra, India, 400055. **Telephone:** +91 22 6288 1111 **Email**: contact@qmsmas.com **Website:** : www.qmsmas.com

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving folio details such as name, address of the Applicant contact numbers), e- mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process) ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as the-case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process).

THE LEVEL OF SUBSCRPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

FOR QMS MEDICAL ALLIED SERVIES Limited
Sd/-
Toral Jailesh Bhadra
Company Secretary & Compliance Officer

Date: September 24, 2025
Place: Mumbai

Disclaimer: The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. NSE at www.nseindia.com and the website of the Registrar to the issue at bigshareonline.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 22 of the Letter of Offer.

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

QMS MEDICAL ALLIED SERVICES LIMITED ("Company" or "Issuer") was incorporated as a private limited company under the Companies Act, 2013 in the name of QMS MEDICAL ALLIED SERVICES PRIVATE LIMITED at Mumbai vide Certificate of Incorporation dated September 14, 2017. Pursuant to conversion of our Company to a public limited company, our name was changed to QMS MEDICAL ALLIED SERVICES LIMITED and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC, Mumbai on November 16, 2020. For details, please refer to the section titled "General Information" beginning on page no. 35 of the Letter of Offer.

Registered Office: AT A1 A2/B1 B2, NAVKALA BHARTI BLDG PLOT NO16 PRABHAT COLONY OPP NEAR SANTACRUZ BUS DEPOT SANTACRUZ EAST, MUMBAI CITY, MUMBAI, MAHARASHTRA, INDIA, 400055
Tel: +91 22 6288 1111 ; Contact Person: Ms. Toral Jailesh Bhadra, Company Secretary and Compliance Officer ;,
E-mail: contact@qmsmas.com; Website: www.qmsmas.com ; Corporate Identification Number: L33309MH2017PLC299748

PROMOTER OF OUR COMPANY: MAHESH MAKHIJA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF QMS MEDICAL ALLIED SERVICES LIMITED (THE "COMPANY" OR "THE ISSUER" ONLY

ISSUE OF 14,87,500 EQUITY SHARES OF FACE VALUE OF Rs. 10.00/- (RIGHTS EQUITY SHARES) OF QMS MEDICAL ALLIED SERVICES LIMITED (THE COMPANY OR THE "ISSUER") FOR CASH AT A PRICE OF Rs. 81/- (RUPEES EIGHTY-ONE ONLY) PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF Rs. 71/- (RUPEES SEVENTY-ONE ONLY) PER RIGHTS EQUITY SHARE) („ISSUE PRICE) FOR AN AMOUNT TO Rs. 12,04,87,500/- (RUPEES TWELVE CRORE FOUR LAKH EIGHTY-SEVEN THOUSAND AND FIVE HUNDRED ONLY) ON A RIGHTS ISSUE BASIS TO THE ELIGIBLE SHAREHOLDERS IN THE RATIO OF ONE RIGHT SHARES FOR EVERY TWELVE EQUITY SHARES HELD BY SUCH ELIGIBLE SHAREHOLDERS AS ON THE RECORD DATE, SEPTEMBER 04, 2025 ("ISSUE").

BASIS OF ALLOTMENT

The Board of Directors of QMS MEDICAL ALLIED SERVICES LIMITED wishes to thank all its members and investors for the overwhelming response to the Company's Rights Issue of Equity Shares, which opened for subscription on Friday, September 12, 2025 and closed on Monday, September 22, 2025 and the last date for market renunciation of Rights Entitlements was on Wednesday, September 17, 2025. In Rights Issue we received total 529 Applications for 22,02,820 Equity Shares (includes 4 applications of 10,71,613 Equity shares by Specific Investor) through Application Supported by Blocked Amount ("ASBA"). Applications for 78767 Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The application for 5 cases having 12,118 Additional Rights Equity Shares were rejected where the shareholder had partly renounced and applied for Additional Rights Equity Shares. The said Applications for 12,118 Additional Rights Equity Shares have not been considered for Allotment. The total number of valid applications received were 296 for 21,24,053 Equity Shares, which aggregates to 142.79% of the total number of Equity Shares allotted under the Issue. In accordance with the LOF the basis of allotment finalized on Tuesday, September 23, 2025 in consultation with the Company, the Registrar to the Issue and National Stock Exchange of India Limited, the Stock Exchange for the Issue. The Company has on Tuesday, September 23, 2025 allotted 14,87,443 Rights Equity Shares to the successful applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. We hereby confirm that all the valid applications have been considered for Allotment.
In accordance with Regulation 86 of SEBI ICDR Regulations, 2018 Our Company is required to achieve minimum subscription for the Rights Issue.

1.Information regarding total number of Applications received:

Category	Applications Received		Equity Shares Applied for			Equity Shares allotted		
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%
Eligible Equity Shareholders	503	95.09 %	9,33,833	7,56,40,473	42.39 %	3,66,196	2,96,61,876	24.62%
Renouncees	22	4.16 %	1,96,295	1,58,99,895	8.91 %	49,551	40,13,631	3.33 %
Specific Investor*	4	0.76 %	10,72,692	8,68,88,052	48.70 %	10,71,696	8,68,07,376	72.05 %
Total	**529**	**100.00%**	**22,02,820**	**17,84,28,420**	**100.00 %**	**14,87,443**	**12,04,82,883**	**100.00 %**

*** In terms of Reg 77B (1) (a)** of SEBI ICDR Regulations, 2018, the Company had published a public advertisement in the newspaper specifying the name of Specific Investor,
The details of Specific Investor from whom applications were received are as mentioned below:

Sr. No	Name of Specific Investor	Equity Shares allotted	Value (Rs)
1	AMRIT KAAL OPPORTUNITIES FUND	3,09,922	2,51,03,682
2	Mr. ASHSISH VASANI	61,918	50,15,358
3	Mr. GUARANG VASANI ON BEHALF OF M/S. STELLAR GROWTH ADVISORS	6,36,693	5,15,72,133
4	Ms. VRANDA RATHI	63,163	51,16,203

2.Basis of Allotment

Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)
	Number	Number	Number	Number
Shareholders	270	2,13,974	1,52,222	3,66,196
Renouncees	22	49,551	0	49,551
Specific Investor	4	10,71,613	83	10,71,696
Total	**296**	**13,35,138**	**1,52,305**	**14,87,443**

Intimations for Allotment/refund/rejection cases: The dispatch of allotment advice cum refund intimation, as applicable, to the investors has been completed on September 24, 2025.The instructions to SCSBs for unblocking funds in case of ASBA Applications were given on September 23, 2025. The Listing application has been filed with NSE on September 24, 2025 and subsequently the Listing approval will be received on or about September 25, 2025. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of allottees will be completed on or about September 25, 2025. No Physical shares were tendered in the Rights Issue. Pursuant to Listing and Trading Approvals granted by National Stock Exchange of India Limited, the Rights Equity Shares Allotted in the issue is expected to commence the trading on National Stock Exchange of India Limited on or about September 26, 2025 and shall be traded under the same ISIN: INE0FMW01018 as the existing Equity Shares. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has be sent to NSDL & CDSL on or about Wednesday, September 24, 2025.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM

DISCLAIMER CLAUSE OF NSE (STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not, in any way, be deemed or construed that the Letter of Offer has been cleared or approved by the NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer in the full text of the "Disclaimer clause of NSE" on page 59 of the Letter of Offer.

Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

REGISTRAR TO THE ISSUE	Company Secretary
Bigshare Services Private Limited **1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400 059, Maharashtra, India.** **Tel No.: +91 22 6263 8200** **Email: rightsissue@bigshareonline.com** **Website:** www.bigshareonline.com **Investor Grievance Email:** investor@bigshareonline.com **Contact Person: Mr. Suraj Gupta** **SEBI Registration No.: INR000001385** **Validity of Registration: Permanent**	**Toral Jailesh Bhadra** A1 A2/B1 B2, Navkala Bharti Bldg , Plot No16 Prabhat Colony, opp near Santacruz Bus depot Santacruz East, Mumbai City, Mumbai, Maharashtra, India, 400055. **Telephone:** +91 22 6288 1111 **Email**: contact@qmsmas.com **Website:** : www.qmsmas.com

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving folio details such as name, address of the Applicant contact numbers), e- mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process) ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as the-case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process).

THE LEVEL OF SUBSCRPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

FOR QMS MEDICAL ALLIED SERVIES Limited
Sd/-
Toral Jailesh Bhadra
Company Secretary & Compliance Officer

Date: September 24, 2025
Place: Mumbai

Disclaimer: The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. NSE at www.nseindia.com and the website of the Registrar to the issue at bigshareonline.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 22 of the Letter of Offer.

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

QMS MEDICAL ALLIED SERVICES LIMITED ("Company" or "Issuer") was incorporated as a private limited company under the Companies Act, 2013 in the name of QMS MEDICAL ALLIED SERVICES PRIVATE LIMITED at Mumbai vide Certificate of Incorporation dated September 14, 2017. Pursuant to conversion of our Company to a public limited company, our name was changed to QMS MEDICAL ALLIED SERVICES LIMITED and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC, Mumbai on November 16, 2020. For details, please refer to the section titled "General Information" beginning on page no. 35 of the Letter of Offer.

Registered Office: AT A1 A2/B1 B2, NAVKALA BHARTI BLDG PLOT NO16 PRABHAT COLONY OPP NEAR SANTACRUZ BUS DEPOT SANTACRUZ EAST, MUMBAI CITY, MUMBAI, MAHARASHTRA, INDIA, 400055
Tel: +91 22 6288 1111 ; Contact Person: Ms. Toral Jailesh Bhadra, Company Secretary and Compliance Officer ;,
E-mail: contact@qmsmas.com; Website: www.qmsmas.com ; Corporate Identification Number: L33309MH2017PLC299748

PROMOTER OF OUR COMPANY: MAHESH MAKHIJA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF QMS MEDICAL ALLIED SERVICES LIMITED (THE "COMPANY" OR "THE ISSUER" ONLY

ISSUE OF 14,87,500 EQUITY SHARES OF FACE VALUE OF Rs. 10.00/- (RIGHTS EQUITY SHARES) OF QMS MEDICAL ALLIED SERVICES LIMITED (THE COMPANY OR THE "ISSUER") FOR CASH AT A PRICE OF Rs. 81/- (RUPEES EIGHTY-ONE ONLY) PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF Rs. 71/- (RUPEES SEVENTY-ONE ONLY) PER RIGHTS EQUITY SHARE) („ISSUE PRICE) FOR AN AMOUNT TO Rs. 12,04,87,500/- (RUPEES TWELVE CRORE FOUR LAKH EIGHTY-SEVEN THOUSAND AND FIVE HUNDRED ONLY) ON A RIGHTS ISSUE BASIS TO THE ELIGIBLE SHAREHOLDERS IN THE RATIO OF ONE RIGHT SHARES FOR EVERY TWELVE EQUITY SHARES HELD BY SUCH ELIGIBLE SHAREHOLDERS AS ON THE RECORD DATE, SEPTEMBER 04, 2025 ("ISSUE").

BASIS OF ALLOTMENT

The Board of Directors of QMS MEDICAL ALLIED SERVICES LIMITED wishes to thank all its members and investors for the overwhelming response to the Company's Rights Issue of Equity Shares, which opened for subscription on Friday, September 12, 2025 and closed on Monday, September 22, 2025 and the last date for market renunciation of Rights Entitlements was on Wednesday, September 17, 2025. In Rights Issue we received total 529 Applications for 22,02,820 Equity Shares (includes 4 applications of 10,71,613 Equity shares by Specific Investor) through Application Supported by Blocked Amount ("ASBA"). Applications for 78767 Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The application for 5 cases having 12,118 Additional Rights Equity Shares were rejected where the shareholder had partly renounced and applied for Additional Rights Equity Shares. The said Applications for 12,118 Additional Rights Equity Shares have not been considered for Allotment. The total number of valid applications received were 296 for 21,24,053 Equity Shares, which aggregates to 142.79% of the total number of Equity Shares allotted under the Issue. In accordance with the LOF the basis of allotment finalized on Tuesday, September 23, 2025 in consultation with the Company, the Registrar to the Issue and National Stock Exchange of India Limited, the Stock Exchange for the Issue. The Company has on Tuesday, September 23, 2025 allotted 14,87,443 Rights Equity Shares to the successful applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. We hereby confirm that all the valid applications have been considered for Allotment.
In accordance with Regulation 86 of SEBI ICDR Regulations, 2018 Our Company is required to achieve minimum subscription for the Rights Issue.

1.Information regarding total number of Applications received:

Category	Applications Received		Equity Shares Applied for			Equity Shares allotted		
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%
Eligible Equity Shareholders	503	95.09 %	9,33,833	7,56,40,473	42.39 %	3,66,196	2,96,61,876	24.62%
Renouncees	22	4.16 %	1,96,295	1,58,99,895	8.91 %	49,551	40,13,631	3.33 %
Specific Investor*	4	0.76 %	10,72,692	8,68,88,052	48.70 %	10,71,696	8,68,07,376	72.05 %
Total	**529**	**100.00%**	**22,02,820**	**17,84,28,420**	**100.00 %**	**14,87,443**	**12,04,82,883**	**100.00 %**

*** In terms of Reg 77B (1) (a)** of SEBI ICDR Regulations, 2018, the Company had published a public advertisement in the newspaper specifying the name of Specific Investor,
The details of Specific Investor from whom applications were received are as mentioned below:

Sr. No	Name of Specific Investor	Equity Shares allotted	Value (Rs)
1	AMRIT KAAL OPPORTUNITIES FUND	3,09,922	2,51,03,682
2	Mr. ASHSISH VASANI	61,918	50,15,358
3	Mr. GUARANG VASANI ON BEHALF OF M/S. STELLAR GROWTH ADVISORS	6,36,693	5,15,72,133
4	Ms. VRANDA RATHI	63,163	51,16,203

2.Basis of Allotment

Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)
	Number	Number	Number	Number
Shareholders	270	2,13,974	1,52,222	3,66,196
Renouncees	22	49,551	0	49,551
Specific Investor	4	10,71,613	83	10,71,696
Total	**296**	**13,35,138**	**1,52,305**	**14,87,443**

Intimations for Allotment/refund/rejection cases: The dispatch of allotment advice cum refund intimation, as applicable, to the investors has been completed on September 24, 2025.The instructions to SCSBs for unblocking funds in case of ASBA Applications were given on September 23, 2025. The Listing application has been filed with NSE on September 24, 2025 and subsequently the Listing approval will be received on or about September 25, 2025. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of allottees will be completed on or about September 25, 2025. No Physical shares were tendered in the Rights Issue. Pursuant to Listing and Trading Approvals granted by National Stock Exchange of India Limited, the Rights Equity Shares Allotted in the issue is expected to commence the trading on National Stock Exchange of India Limited on or about September 26, 2025 and shall be traded under the same ISIN: INE0FMW01018 as the existing Equity Shares. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has been sent to NSDL & CDSL on or about Wednesday, September 24, 2025.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM

DISCLAIMER CLAUSE OF NSE (STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not, in any way, be deemed or construed that the Letter of Offer has been cleared or approved by the NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer in the full text of the "Disclaimer clause of NSE" on page 59 of the Letter of Offer.

Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

REGISTRAR TO THE ISSUE	Company Secretary
Bigshare Services Private Limited 1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400 059, Maharashtra, India. Tel No.: +91 22 6263 8200 Email: rightsissue@bigshareonline.com Website: www.bigshareonline.com Investor Grievance Email: investor@bigshareonline.com Contact Person: Mr. Suraj Gupta SEBI Registration No.: INR000001385 Validity of Registration: Permanent	**Toral Jailesh Bhadra** A1 A2/B1 B2, Navkala Bharti Bldg , Plot No16 Prabhat Colony, opp near Santacruz Bus depot Santacruz East, Mumbai City, Mumbai, Maharashtra, India, 400055. **Telephone:** +91 22 6288 1111 **Email**: contact@qmsmas.com **Website:** : www.qmsmas.com

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving folio details such as name, address of the Applicant contact numbers), e- mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process) ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as the-case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process).

THE LEVEL OF SUBSCRPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

FOR QMS MEDICAL ALLIED SERVIES Limited
Sd/-
Toral Jailesh Bhadra
Company Secretary & Compliance Officer

Date: September 24, 2025
Place: Mumbai

Disclaimer: The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. NSE at www.nseindia.com and the website of the Registrar to the issue at bigshareonline.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 22 of the Letter of Offer.

QMS MEDICAL ALLIED SERVICES

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

QMS MEDICAL ALLIED SERVICES LIMITED ("Company" or "Issuer") was incorporated as a private limited company under the Companies Act, 2013 in the name of QMS MEDICAL ALLIED SERVICES PRIVATE LIMITED at Mumbai vide Certificate of Incorporation dated September 14, 2017. Pursuant to conversion of our Company to a public limited company, our name was changed to QMS MEDICAL ALLIED SERVICES LIMITED and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC, Mumbai on November 16, 2020. For details, please refer to the section titled "General Information" beginning on page no. 35 of the Letter of Offer.

Registered Office: AT A1 A2/B1 B2, NAVKALA BHARTI BLDG PLOT NO16 PRABHAT COLONY OPP NEAR SANTACRUZ BUS DEPOT SANTACRUZ EAST, MUMBAI CITY, MUMBAI, MAHARASHTRA, INDIA, 400055
Tel: +91 22 6288 1111 ; Contact Person: Ms. Toral Jailesh Bhadra, Company Secretary and Compliance Officer ;,
E-mail: contact@qmsmas.com; Website: www.qmsmas.com ; Corporate Identification Number: L33309MH2017PLC299748

PROMOTER OF OUR COMPANY: MAHESH MAKHIJA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF QMS MEDICAL ALLIED SERVICES LIMITED (THE "COMPANY" OR "THE ISSUER" ONLY

ISSUE OF 14,87,500 EQUITY SHARES OF FACE VALUE OF Rs. 10.00/- (RIGHTS EQUITY SHARES) OF QMS MEDICAL ALLIED SERVICES LIMITED (THE COMPANY OR THE "ISSUER") FOR CASH AT A PRICE OF Rs. 81/- (RUPEES EIGHTY-ONE ONLY) PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF Rs. 71/- (RUPEES SEVENTY-ONE ONLY) PER RIGHTS EQUITY SHARE) („ISSUE PRICE) FOR AN AMOUNT TO Rs. 12,04,87,500/- (RUPEES TWELVE CRORE FOUR LAKH EIGHTY-SEVEN THOUSAND AND FIVE HUNDRED ONLY) ON A RIGHTS ISSUE BASIS TO THE ELIGIBLE SHAREHOLDERS IN THE RATIO OF ONE RIGHT SHARES FOR EVERY TWELVE EQUITY SHARES HELD BY SUCH ELIGIBLE SHAREHOLDERS AS ON THE RECORD DATE, SEPTEMBER 04, 2025 ("ISSUE").

BASIS OF ALLOTMENT

The Board of Directors of QMS MEDICAL ALLIED SERVICES LIMITED wishes to thank all its members and investors for the overwhelming response to the Company's Rights Issue of Equity Shares, which opened for subscription on Friday, September 12, 2025 and closed on Monday, September 22, 2025 and the last date for market renunciation of Rights Entitlements was on Wednesday, September 17, 2025. In Rights Issue we received total 529 Applications for 22,02,820 Equity Shares (includes 4 applications of 10,71,613 Equity shares by Specific Investor) through Application Supported by Blocked Amount ("ASBA"). Applications for 78767 Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The application for 5 cases having 12,118 Additional Rights Equity Shares were rejected where the shareholder had partly renounced and applied for Additional Rights Equity Shares. The said Applications for 12,118 Additional Rights Equity Shares have not been considered for Allotment. The total number of valid applications received were 296 for 21,24,053 Equity Shares, which aggregates to 142.79% of the total number of Equity Shares allotted under the Issue. In accordance with the LOF the basis of allotment finalized on Tuesday, September 23, 2025 in consultation with the Company, the Registrar to the Issue and National Stock Exchange of India Limited, the Stock Exchange for the Issue. The Company has on Tuesday, September 23, 2025 allotted 14,87,443 Rights Equity Shares to the successful applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. We hereby confirm that all the valid applications have been considered for Allotment.
In accordance with Regulation 86 of SEBI ICDR Regulations, 2018 Our Company is required to achieve minimum subscription for the Rights Issue.

1.Information regarding total number of Applications received:

Category	Applications Received		Equity Shares Applied for			Equity Shares allotted		
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%
Eligible Equity Shareholders	503	95.09 %	9,33,833	7,56,40,473	42.39 %	3,66,196	2,96,61,876	24.62%
Renouncees	22	4.16 %	1,96,295	1,58,99,895	8.91 %	49,551	40,13,631	3.33 %
Specific Investor*	4	0.76 %	10,72,692	8,68,88,052	48.70 %	10,71,696	8,68,07,376	72.05 %
Total	**529**	**100.00%**	**22,02,820**	**17,84,28,420**	**100.00 %**	**14,87,443**	**12,04,82,883**	**100.00 %**

*** In terms of Reg 77B (1) (a)** of SEBI ICDR Regulations, 2018, the Company had published a public advertisement in the newspaper specifying the name of Specific Investor,
The details of Specific Investor from whom applications were received are as mentioned below:

Sr. No	Name of Specific Investor	Equity Shares allotted	Value (Rs)
1	AMRIT KAAL OPPORTUNITIES FUND	3,09,922	2,51,03,682
2	Mr. ASHSISH VASANI	61,918	50,15,358
3	Mr. GUARANG VASANI ON BEHALF OF M/S. STELLAR GROWTH ADVISORS	6,36,693	5,15,72,133
4	Ms. VRANDA RATHI	63,163	51,16,203

2.Basis of Allotment

Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)
	Number	Number	Number	Number
Shareholders	270	2,13,974	1,52,222	3,66,196
Renouncees	22	49,551	0	49,551
Specific Investor	4	10,71,613	83	10,71,696
Total	**296**	**13,35,138**	**1,52,305**	**14,87,443**

Intimations for Allotment/refund/rejection cases: The dispatch of allotment advice cum refund intimation, as applicable, to the investors has been completed on September 24, 2025.The instructions to SCSBs for unblocking funds in case of ASBA Applications were given on September 23, 2025. The Listing application has been filed with NSE on September 24, 2025 and subsequently the Listing approval will be received on or about September 25, 2025. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of allottees will be completed on or about September 25, 2025. No Physical shares were tendered in the Rights Issue. Pursuant to Listing and Trading Approvals granted by National Stock Exchange of India Limited, the Rights Equity Shares Allotted in the issue is expected to commence the trading on National Stock Exchange of India Limited on or about September 26, 2025 and shall be traded under the same ISIN: INE0FMW01018 as the existing Equity Shares. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has be sent to NSDL & CDSL on or about Wednesday, September 24, 2025.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM

DISCLAIMER CLAUSE OF NSE (STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not, in any way, be deemed or construed that the Letter of Offer has been cleared or approved by the NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer in the full text of the "Disclaimer clause of NSE" on page 59 of the Letter of Offer.

Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

REGISTRAR TO THE ISSUE	Company Secretary
Bigshare Services Private Limited **1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400 059, Maharashtra, India.** **Tel No.: +91 22 6263 8200** **Email: rightsissue@bigshareonline.com** **Website:** www.bigshareonline.com **Investor Grievance Email:** investor@bigshareonline.com **Contact Person: Mr. Suraj Gupta** **SEBI Registration No.: INR000001385** **Validity of Registration: Permanent**	QMS MEDICAL ALLIED SERVICES **Toral Jailesh Bhadra** A1 A2/B1 B2, Navkala Bharti Bldg , Plot No16 Prabhat Colony, opp near Santacruz Bus depot Santacruz East, Mumbai City, Mumbai, Maharashtra, India, 400055. **Telephone:** +91 22 6288 1111 **Email**: contact@qmsmas.com **Website:** : www.qmsmas.com

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving folio details such as name, address of the Applicant contact numbers), e- mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process) ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as the-case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process).

THE LEVEL OF SUBSCRPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

FOR QMS MEDICAL ALLIED SERVIES Limited
Sd/-
Toral Jailesh Bhadra
Company Secretary & Compliance Officer

Date: September 24, 2025
Place: Mumbai

Disclaimer: The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. NSE at www.nseindia.com and the website of the Registrar to the issue at bigshareonline.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 22 of the Letter of Offer.

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

QMS MEDICAL ALLIED SERVICES LIMITED ("Company" or "Issuer") was incorporated as a private limited company under the Companies Act, 2013 in the name of QMS MEDICAL ALLIED SERVICES PRIVATE LIMITED at Mumbai vide Certificate of Incorporation dated September 14, 2017. Pursuant to conversion of our Company to a public limited company, our name was changed to QMS MEDICAL ALLIED SERVICES LIMITED and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC, Mumbai on November 16, 2020. For details, please refer to the section titled "General Information" beginning on page no. 35 of the Letter of Offer.

Registered Office: AT A1 A2/B1 B2, NAVKALA BHARTI BLDG PLOT NO16 PRABHAT COLONY OPP NEAR SANTACRUZ BUS DEPOT SANTACRUZ EAST, MUMBAI CITY, MUMBAI, MAHARASHTRA, INDIA, 400055
Tel: +91 22 6288 1111 ; Contact Person: Ms. Toral Jailesh Bhadra, Company Secretary and Compliance Officer ;,
E-mail: contact@qmsmas.com; Website: www.qmsmas.com ; Corporate Identification Number: L33309MH2017PLC299748

PROMOTER OF OUR COMPANY: MAHESH MAKHIJA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF QMS MEDICAL ALLIED SERVICES LIMITED (THE "COMPANY" OR "THE ISSUER" ONLY

ISSUE OF 14,87,500 EQUITY SHARES OF FACE VALUE OF Rs. 10.00/- (RIGHTS EQUITY SHARES) OF QMS MEDICAL ALLIED SERVICES LIMITED (THE COMPANY OR THE "ISSUER") FOR CASH AT A PRICE OF Rs. 81/- (RUPEES EIGHTY-ONE ONLY) PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF Rs. 71/- (RUPEES SEVENTY-ONE ONLY) PER RIGHTS EQUITY SHARE) („ISSUE PRICE) FOR AN AMOUNT TO Rs. 12,04,87,500/- (RUPEES TWELVE CRORE FOUR LAKH EIGHTY-SEVEN THOUSAND AND FIVE HUNDRED ONLY) ON A RIGHTS ISSUE BASIS TO THE ELIGIBLE SHAREHOLDERS IN THE RATIO OF ONE RIGHT SHARES FOR EVERY TWELVE EQUITY SHARES HELD BY SUCH ELIGIBLE SHAREHOLDERS AS ON THE RECORD DATE, SEPTEMBER 04, 2025 ("ISSUE").

BASIS OF ALLOTMENT

The Board of Directors of QMS MEDICAL ALLIED SERVICES LIMITED wishes to thank all its members and investors for the overwhelming response to the Company's Rights Issue of Equity Shares, which opened for subscription on Friday, September 12, 2025 and closed on Monday, September 22, 2025 and the last date for market renunciation of Rights Entitlements was on Wednesday, September 17, 2025. In Rights Issue we received total 529 Applications for 22,02,820 Equity Shares (includes 4 applications of 10,71,613 Equity shares by Specific Investor) through Application Supported by Blocked Amount ("ASBA"). Applications for 78767 Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The application for 5 cases having 12,118 Additional Rights Equity Shares were rejected where the shareholder had partly renounced and applied for Additional Rights Equity Shares. The said Applications for 12,118 Additional Rights Equity Shares have not been considered for Allotment. The total number of valid applications received were 296 for 21,24,053 Equity Shares, which aggregates to 142.79% of the total number of Equity Shares allotted under the Issue. In accordance with the LOF the basis of allotment finalized on Tuesday, September 23, 2025 in consultation with the Company, the Registrar to the Issue and National Stock Exchange of India Limited, the Stock Exchange for the Issue. The Company has on Tuesday, September 23, 2025 allotted 14,87,443 Rights Equity Shares to the successful applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. We hereby confirm that all the valid applications have been considered for Allotment.
In accordance with Regulation 86 of SEBI ICDR Regulations, 2018 Our Company is required to achieve minimum subscription for the Rights Issue.

1.Information regarding total number of Applications received:

Category	Applications Received		Equity Shares Applied for			Equity Shares allotted		
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%
Eligible Equity Shareholders	503	95.09 %	9,33,833	7,56,40,473	42.39 %	3,66,196	2,96,61,876	24.62%
Renouncees	22	4.16 %	1,96,295	1,58,99,895	8.91 %	49,551	40,13,631	3.33 %
Specific Investor*	4	0.76 %	10,72,692	8,68,88,052	48.70 %	10,71,696	8,68,07,376	72.05 %
Total	**529**	**100.00%**	**22,02,820**	**17,84,28,420**	**100.00 %**	**14,87,443**	**12,04,82,883**	**100.00 %**

*** In terms of Reg 77B (1) (a)** of SEBI ICDR Regulations, 2018, the Company had published a public advertisement in the newspaper specifying the name of Specific Investor,
The details of Specific Investor from whom applications were received are as mentioned below:

Sr. No	Name of Specific Investor	Equity Shares allotted	Value (Rs)
1	AMRIT KAAL OPPORTUNITIES FUND	3,09,922	2,51,03,682
2	Mr. ASHSISH VASANI	61,918	50,15,358
3	Mr. GUARANG VASANI ON BEHALF OF M/S. STELLAR GROWTH ADVISORS	6,36,693	5,15,72,133
4	Ms. VRANDA RATHI	63,163	51,16,203

2.Basis of Allotment

Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)
	Number	Number	Number	Number
Shareholders	270	2,13,974	1,52,222	3,66,196
Renouncees	22	49,551	0	49,551
Specific Investor	4	10,71,613	83	10,71,696
Total	**296**	**13,35,138**	**1,52,305**	**14,87,443**

Intimations for Allotment/refund/rejection cases: The dispatch of allotment advice cum refund intimation, as applicable, to the investors has been completed on September 24, 2025.The instructions to SCSBs for unblocking funds in case of ASBA Applications were given on September 23, 2025. The Listing application has been filed with NSE on September 24, 2025 and subsequently the Listing approval will be received on or about September 25, 2025. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of allottees will be completed on or about September 25, 2025. No Physical shares were tendered in the Rights Issue. Pursuant to Listing and Trading Approvals granted by National Stock Exchange of India Limited, the Rights Equity Shares Allotted in the issue is expected to commence the trading on National Stock Exchange of India Limited on or about September 26, 2025 and shall be traded under the same ISIN: INE0FMW01018 as the existing Equity Shares. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has be sent to NSDL & CDSL on or about Wednesday, September 24, 2025.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM

DISCLAIMER CLAUSE OF NSE (STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not, in any way, be deemed or construed that the Letter of Offer has been cleared or approved by the NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer in the full text of the "Disclaimer clause of NSE" on page 59 of the Letter of Offer.

Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

REGISTRAR TO THE ISSUE	Company Secretary
Bigshare Services Private Limited **1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400 059, Maharashtra, India.** **Tel No.: +91 22 6263 8200** **Email: rightsissue@bigshareonline.com** **Website:** www.bigshareonline.com **Investor Grievance Email:** investor@bigshareonline.com **Contact Person: Mr. Suraj Gupta** **SEBI Registration No.: INR000001385** **Validity of Registration: Permanent**	**Toral Jailesh Bhadra** A1 A2/B1 B2, Navkala Bharti Bldg , Plot No16 Prabhat Colony, opp near Santacruz Bus depot Santacruz East, Mumbai City, Mumbai, Maharashtra, India, 400055. **Telephone:** +91 22 6288 1111 **Email**: contact@qmsmas.com **Website:** : www.qmsmas.com

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving folio details such as name, address of the Applicant contact numbers), e- mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process) ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as the-case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process).

THE LEVEL OF SUBSCRPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

FOR QMS MEDICAL ALLIED SERVIES Limited
Sd/-
Toral Jailesh Bhadra
Company Secretary & Compliance Officer

Date: September 24, 2025
Place: Mumbai

Disclaimer: The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. NSE at www.nseindia.com and the website of the Registrar to the issue at bigshareonline.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 22 of the Letter of Offer.

(This is only an Advertisement for information purpose and not an offer document announcement. Not for publication, distribution or release directly or indirectly into the United States or otherwise outside India.
All capitalized terms used and not defined herein shall have the meaning assigned to them in Letter of Offer dated August 29, 2025 ("the Letter of Offer" or "LOF") filed with National Stock Exchange of India and the Securities and Exchange Board of India ("SEBI").

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

QMS MEDICAL ALLIED SERVICES LIMITED ("Company" or "Issuer") was incorporated as a private limited company under the Companies Act, 2013 in the name of QMS MEDICAL ALLIED SERVICES PRIVATE LIMITED at Mumbai vide Certificate of Incorporation dated September 14, 2017. Pursuant to conversion of our Company to a public limited company, our name was changed to QMS MEDICAL ALLIED SERVICES LIMITED and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC, Mumbai on November 16, 2020. For details, please refer to the section titled "General Information" beginning on page no. 35 of the Letter of Offer.

Registered Office: AT A1 A2/B1 B2, NAVKALA BHARTI BLDG PLOT NO16 PRABHAT COLONY OPP NEAR SANTACRUZ BUS DEPOT SANTACRUZ EAST, MUMBAI CITY, MUMBAI, MAHARASHTRA, INDIA, 400055
Tel: +91 22 6288 1111 ; Contact Person: Ms. Toral Jailesh Bhadra, Company Secretary and Compliance Officer ;,
E-mail: contact@qmsmas.com; Website: www.qmsmas.com ; Corporate Identification Number: L33309MH2017PLC299748

PROMOTER OF OUR COMPANY: MAHESH MAKHIJA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF QMS MEDICAL ALLIED SERVICES LIMITED (THE "COMPANY" OR "THE ISSUER" ONLY

ISSUE OF 14,87,500 EQUITY SHARES OF FACE VALUE OF Rs. 10.00/- (RIGHTS EQUITY SHARES) OF QMS MEDICAL ALLIED SERVICES LIMITED (THE COMPANY OR THE "ISSUER") FOR CASH AT A PRICE OF Rs. 81/- (RUPEES EIGHTY-ONE ONLY) PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF Rs. 71/- (RUPEES SEVENTY-ONE ONLY) PER RIGHTS EQUITY SHARE) („ISSUE PRICE) FOR AN AMOUNT TO Rs. 12,04,87,500/- (RUPEES TWELVE CRORE FOUR LAKH EIGHTY-SEVEN THOUSAND AND FIVE HUNDRED ONLY) ON A RIGHTS ISSUE BASIS TO THE ELIGIBLE SHAREHOLDERS IN THE RATIO OF ONE RIGHT SHARES FOR EVERY TWELVE EQUITY SHARES HELD BY SUCH ELIGIBLE SHAREHOLDERS AS ON THE RECORD DATE, SEPTEMBER 04, 2025 ("ISSUE").

BASIS OF ALLOTMENT

The Board of Directors of QMS MEDICAL ALLIED SERVICES LIMITED wishes to thank all its members and investors for the overwhelming response to the Company's Rights Issue of Equity Shares, which opened for subscription on Friday, September 12, 2025 and closed on Monday, September 22, 2025 and the last date for market renunciation of Rights Entitlements was on Wednesday, September 17, 2025. In Rights Issue we received total 529 Applications for 22,02,820 Equity Shares (includes 4 applications of 10,71,613 Equity shares by Specific Investor) through Application Supported by Blocked Amount ("ASBA"). Applications for 78767 Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The application for 5 cases having 12,118 Additional Rights Equity Shares were rejected where the shareholder had partly renounced and applied for Additional Rights Equity Shares. The said Applications for 12,118 Additional Rights Equity Shares have not been considered for Allotment. The total number of valid applications received were 296 for 21,24,053 Equity Shares, which aggregates to 142.79% of the total number of Equity Shares allotted under the Issue. In accordance with the LOF the basis of allotment finalized on Tuesday, September 23, 2025 in consultation with the Company, the Registrar to the Issue and National Stock Exchange of India Limited, the Stock Exchange for the Issue. The Company has on Tuesday, September 23, 2025 allotted 14,87,443 Rights Equity Shares to the successful applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. We hereby confirm that all the valid applications have been considered for Allotment.
In accordance with Regulation 86 of SEBI ICDR Regulations, 2018 Our Company is required to achieve minimum subscription for the Rights Issue.

1.Information regarding total number of Applications received:

Category	Applications Received		Equity Shares Applied for			Equity Shares allotted		
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%
Eligible Equity Shareholders	503	95.09 %	9,33,833	7,56,40,473	42.39 %	3,66,196	2,96,61,876	24.62%
Renouncees	22	4.16 %	1,96,295	1,58,99,895	8.91 %	49,551	40,13,631	3.33 %
Specific Investor*	4	0.76 %	10,72,692	8,68,88,052	48.70 %	10,71,696	8,68,07,376	72.05 %
Total	**529**	**100.00%**	**22,02,820**	**17,84,28,420**	**100.00 %**	**14,87,443**	**12,04,82,883**	**100.00 %**

*** In terms of Reg 77B (1) (a)** of SEBI ICDR Regulations, 2018, the Company had published a public advertisement in the newspaper specifying the name of Specific Investor,
The details of Specific Investor from whom applications were received are as mentioned below:

Sr. No	Name of Specific Investor	Equity Shares allotted	Value (Rs)
1	AMRIT KAAL OPPORTUNITIES FUND	3,09,922	2,51,03,682
2	Mr. ASHSISH VASANI	61,918	50,15,358
3	Mr. GUARANG VASANI ON BEHALF OF M/S. STELLAR GROWTH ADVISORS	6,36,693	5,15,72,133
4	Ms. VRANDA RATHI	63,163	51,16,203

2.Basis of Allotment

Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)
	Number	Number	Number	Number
Shareholders	270	2,13,974	1,52,222	3,66,196
Renouncees	22	49,551	0	49,551
Specific Investor	4	10,71,613	83	10,71,696
Total	**296**	**13,35,138**	**1,52,305**	**14,87,443**

Intimations for Allotment/refund/rejection cases: The dispatch of allotment advice cum refund intimation, as applicable, to the investors has been completed on September 24, 2025.The instructions to SCSBs for unblocking funds in case of ASBA Applications were given on September 23, 2025. The Listing application has been filed with NSE on September 24, 2025 and subsequently the Listing approval will be received on or about September 25, 2025. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of allottees will be completed on or about September 25, 2025. No Physical shares were tendered in the Rights Issue. Pursuant to Listing and Trading Approvals granted by National Stock Exchange of India Limited, the Rights Equity Shares Allotted in the issue is expected to commence the trading on National Stock Exchange of India Limited on or about September 26, 2025 and shall be traded under the same ISIN: INE0FMW01018 as the existing Equity Shares. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has be sent to NSDL & CDSL on or about Wednesday, September 24, 2025.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM

DISCLAIMER CLAUSE OF NSE (STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not, in any way, be deemed or construed that the Letter of Offer has been cleared or approved by the NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer in the full text of the "Disclaimer clause of NSE" on page 59 of the Letter of Offer.

Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

REGISTRAR TO THE ISSUE	Company Secretary
Bigshare Services Private Limited **1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400 059, Maharashtra, India.** **Tel No.: +91 22 6263 8200** **Email: rightsissue@bigshareonline.com** **Website:** www.bigshareonline.com **Investor Grievance Email:** investor@bigshareonline.com **Contact Person: Mr. Suraj Gupta** **SEBI Registration No.: INR000001385** **Validity of Registration: Permanent**	**Toral Jailesh Bhadra** A1 A2/B1 B2, Navkala Bharti Bldg , Plot No16 Prabhat Colony, opp near Santacruz Bus depot Santacruz East, Mumbai City, Mumbai, Maharashtra, India, 400055. **Telephone:** +91 22 6288 1111 **Email**: contact@qmsmas.com **Website:** : www.qmsmas.com

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving folio details such as name, address of the Applicant contact numbers), e- mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process) ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as the-case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process).

THE LEVEL OF SUBSCRPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

FOR QMS MEDICAL ALLIED SERVIES Limited
Sd/-
Toral Jailesh Bhadra
Company Secretary & Compliance Officer

Date: September 24, 2025
Place: Mumbai

Disclaimer: The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. NSE at www.nseindia.com and the website of the Registrar to the issue at bigshareonline.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 22 of the Letter of Offer.

(This is only an Advertisement for information purpose and not an offer document announcement. Not for publication, distribution or release directly or indirectly into the United States or otherwise outside India.
All capitalized terms used and not defined herein shall have the meaning assigned to them in Letter of Offer dated August 29, 2025 ("the Letter of Offer" or "LOF") filed with National Stock Exchange of India and the Securities and Exchange Board of India ("SEBI").

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

QMS MEDICAL ALLIED SERVICES LIMITED ("Company" or "Issuer") was incorporated as a private limited company under the Companies Act, 2013 in the name of QMS MEDICAL ALLIED SERVICES PRIVATE LIMITED at Mumbai vide Certificate of Incorporation dated September 14, 2017. Pursuant to conversion of our Company to a public limited company, our name was changed to QMS MEDICAL ALLIED SERVICES LIMITED and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC, Mumbai on November 16, 2020. For details, please refer to the section titled "General Information" beginning on page no. 35 of the Letter of Offer.

Registered Office: AT A1 A2/B1 B2, NAVKALA BHARTI BLDG PLOT NO16 PRABHAT COLONY OPP NEAR SANTACRUZ BUS DEPOT SANTACRUZ EAST, MUMBAI CITY, MUMBAI, MAHARASHTRA, INDIA, 400055
Tel: +91 22 6288 1111 ; Contact Person: Ms. Toral Jailesh Bhadra, Company Secretary and Compliance Officer ;,
E-mail: contact@qmsmas.com; Website: www.qmsmas.com ; Corporate Identification Number: L33309MH2017PLC299748

PROMOTER OF OUR COMPANY: MAHESH MAKHIJA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF QMS MEDICAL ALLIED SERVICES LIMITED (THE "COMPANY" OR "THE ISSUER" ONLY

ISSUE OF 14,87,500 EQUITY SHARES OF FACE VALUE OF Rs. 10.00/- (RIGHTS EQUITY SHARES) OF QMS MEDICAL ALLIED SERVICES LIMITED (THE COMPANY OR THE "ISSUER") FOR CASH AT A PRICE OF Rs. 81/- (RUPEES EIGHTY-ONE ONLY) PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF Rs. 71/- (RUPEES SEVENTY-ONE ONLY) PER RIGHTS EQUITY SHARE) („ISSUE PRICE) FOR AN AMOUNT TO Rs. 12,04,87,500/- (RUPEES TWELVE CRORE FOUR LAKH EIGHTY-SEVEN THOUSAND AND FIVE HUNDRED ONLY) ON A RIGHTS ISSUE BASIS TO THE ELIGIBLE SHAREHOLDERS IN THE RATIO OF ONE RIGHT SHARES FOR EVERY TWELVE EQUITY SHARES HELD BY SUCH ELIGIBLE SHAREHOLDERS AS ON THE RECORD DATE, SEPTEMBER 04, 2025 ("ISSUE").

BASIS OF ALLOTMENT

The Board of Directors of QMS MEDICAL ALLIED SERVICES LIMITED wishes to thank all its members and investors for the overwhelming response to the Company's Rights Issue of Equity Shares, which opened for subscription on Friday, September 12, 2025 and closed on Monday, September 22, 2025 and the last date for market renunciation of Rights Entitlements was on Wednesday, September 17, 2025. In Rights Issue we received total 529 Applications for 22,02,820 Equity Shares (includes 4 applications of 10,71,613 Equity shares by Specific Investor) through Application Supported by Blocked Amount ("ASBA"). Applications for 78767 Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The application for 5 cases having 12,118 Additional Rights Equity Shares were rejected where the shareholder had partly renounced and applied for Additional Rights Equity Shares. The said Applications for 12,118 Additional Rights Equity Shares have not been considered for Allotment. The total number of valid applications received were 296 for 21,24,053 Equity Shares, which aggregates to 142.79% of the total number of Equity Shares allotted under the Issue. In accordance with the LOF the basis of allotment finalized on Tuesday, September 23, 2025 in consultation with the Company, the Registrar to the Issue and National Stock Exchange of India Limited, the Stock Exchange for the Issue. The Company has on Tuesday, September 23, 2025 allotted 14,87,443 Rights Equity Shares to the successful applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. We hereby confirm that all the valid applications have been considered for Allotment.
In accordance with Regulation 86 of SEBI ICDR Regulations, 2018 Our Company is required to achieve minimum subscription for the Rights Issue.

1.Information regarding total number of Applications received:

Category	Applications Received		Equity Shares Applied for			Equity Shares allotted		
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%
Eligible Equity Shareholders	503	95.09 %	9,33,833	7,56,40,473	42.39 %	3,66,196	2,96,61,876	24.62%
Renouncees	22	4.16 %	1,96,295	1,58,99,895	8.91 %	49,551	40,13,631	3.33 %
Specific Investor*	4	0.76 %	10,72,692	8,68,88,052	48.70 %	10,71,696	8,68,07,376	72.05 %
Total	**529**	**100.00%**	**22,02,820**	**17,84,28,420**	**100.00 %**	**14,87,443**	**12,04,82,883**	**100.00 %**

*** In terms of Reg 77B (1) (a)** of SEBI ICDR Regulations, 2018, the Company had published a public advertisement in the newspaper specifying the name of Specific Investor,
The details of Specific Investor from whom applications were received are as mentioned below:

Sr. No	Name of Specific Investor	Equity Shares allotted	Value (Rs)
1	AMRIT KAAL OPPORTUNITIES FUND	3,09,922	2,51,03,682
2	Mr. ASHSISH VASANI	61,918	50,15,358
3	Mr. GUARANG VASANI ON BEHALF OF M/S. STELLAR GROWTH ADVISORS	6,36,693	5,15,72,133
4	Ms. VRANDA RATHI	63,163	51,16,203

2.Basis of Allotment

Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)
	Number	Number	Number	Number
Shareholders	270	2,13,974	1,52,222	3,66,196
Renouncees	22	49,551	0	49,551
Specific Investor	4	10,71,613	83	10,71,696
Total	**296**	**13,35,138**	**1,52,305**	**14,87,443**

Intimations for Allotment/refund/rejection cases: The dispatch of allotment advice cum refund intimation, as applicable, to the investors has been completed on September 24, 2025.The instructions to SCSBs for unblocking funds in case of ASBA Applications were given on September 23, 2025. The Listing application has been filed with NSE on September 24, 2025 and subsequently the Listing approval will be received on or about September 25, 2025. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of allottees will be completed on or about September 25, 2025. No Physical shares were tendered in the Rights Issue. Pursuant to Listing and Trading Approvals granted by National Stock Exchange of India Limited, the Rights Equity Shares Allotted in the issue is expected to commence the trading on National Stock Exchange of India Limited on or about September 26, 2025 and shall be traded under the same ISIN: INE0FMW01018 as the existing Equity Shares. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has be sent to NSDL & CDSL on or about Wednesday, September 24, 2025.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM

DISCLAIMER CLAUSE OF NSE (STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not, in any way, be deemed or construed that the Letter of Offer has been cleared or approved by the NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer in the full text of the "Disclaimer clause of NSE" on page 59 of the Letter of Offer.

Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

REGISTRAR TO THE ISSUE	Company Secretary
Bigshare Services Private Limited **1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400 059, Maharashtra, India.** **Tel No.: +91 22 6263 8200** **Email: rightsissue@bigshareonline.com** **Website:** www.bigshareonline.com **Investor Grievance Email:** investor@bigshareonline.com **Contact Person: Mr. Suraj Gupta** **SEBI Registration No.: INR000001385** **Validity of Registration: Permanent**	**Toral Jailesh Bhadra** A1 A2/B1 B2, Navkala Bharti Bldg , Plot No16 Prabhat Colony, opp near Santacruz Bus depot Santacruz East, Mumbai City, Mumbai, Maharashtra, India, 400055. **Telephone:** +91 22 6288 1111 **Email**: contact@qmsmas.com **Website:** : www.qmsmas.com

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving folio details such as name, address of the Applicant contact numbers), e- mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process) ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as the-case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process).

THE LEVEL OF SUBSCRPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

FOR QMS MEDICAL ALLIED SERVIES Limited
Sd/-
Toral Jailesh Bhadra
Company Secretary & Compliance Officer

Date: September 24, 2025
Place: Mumbai

Disclaimer: The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. NSE at www.nseindia.com and the website of the Registrar to the issue at bigshareonline.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 22 of the Letter of Offer.

(This is only an Advertisement for information purpose and not an offer document announcement. Not for publication, distribution or release directly or indirectly into the United States or otherwise outside India.
All capitalized terms used and not defined herein shall have the meaning assigned to them in Letter of Offer dated August 29, 2025 ("the Letter of Offer" or "LOF") filed with National Stock Exchange of India and the Securities and Exchange Board of India ("SEBI").

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

QMS MEDICAL ALLIED SERVICES LIMITED ("Company" or "Issuer") was incorporated as a private limited company under the Companies Act, 2013 in the name of QMS MEDICAL ALLIED SERVICES PRIVATE LIMITED at Mumbai vide Certificate of Incorporation dated September 14, 2017. Pursuant to conversion of our Company to a public limited company, our name was changed to QMS MEDICAL ALLIED SERVICES LIMITED and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC, Mumbai on November 16, 2020. For details, please refer to the section titled "General Information" beginning on page no. 35 of the Letter of Offer.

Registered Office: AT A1 A2/B1 B2, NAVKALA BHARTI BLDG PLOT NO16 PRABHAT COLONY OPP NEAR SANTACRUZ BUS DEPOT SANTACRUZ EAST, MUMBAI CITY, MUMBAI, MAHARASHTRA, INDIA, 400055
Tel: +91 22 6288 1111 ; Contact Person: Ms. Toral Jailesh Bhadra, Company Secretary and Compliance Officer ;,
E-mail: contact@qmsmas.com; Website: www.qmsmas.com ; Corporate Identification Number: L33309MH2017PLC299748

PROMOTER OF OUR COMPANY: MAHESH MAKHIJA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF QMS MEDICAL ALLIED SERVICES LIMITED (THE "COMPANY" OR "THE ISSUER" ONLY

ISSUE OF 14,87,500 EQUITY SHARES OF FACE VALUE OF Rs. 10.00/- (RIGHTS EQUITY SHARES) OF QMS MEDICAL ALLIED SERVICES LIMITED (THE COMPANY OR THE "ISSUER") FOR CASH AT A PRICE OF Rs. 81/- (RUPEES EIGHTY-ONE ONLY) PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF Rs. 71/- (RUPEES SEVENTY-ONE ONLY) PER RIGHTS EQUITY SHARE) („ISSUE PRICE) FOR AN AMOUNT TO Rs. 12,04,87,500/- (RUPEES TWELVE CRORE FOUR LAKH EIGHTY-SEVEN THOUSAND AND FIVE HUNDRED ONLY) ON A RIGHTS ISSUE BASIS TO THE ELIGIBLE SHAREHOLDERS IN THE RATIO OF ONE RIGHT SHARES FOR EVERY TWELVE EQUITY SHARES HELD BY SUCH ELIGIBLE SHAREHOLDERS AS ON THE RECORD DATE, SEPTEMBER 04, 2025 ("ISSUE").

BASIS OF ALLOTMENT

The Board of Directors of QMS MEDICAL ALLIED SERVICES LIMITED wishes to thank all its members and investors for the overwhelming response to the Company's Rights Issue of Equity Shares, which opened for subscription on Friday, September 12, 2025 and closed on Monday, September 22, 2025 and the last date for market renunciation of Rights Entitlements was on Wednesday, September 17, 2025. In Rights Issue we received total 529 Applications for 22,02,820 Equity Shares (includes 4 applications of 10,71,613 Equity shares by Specific Investor) through Application Supported by Blocked Amount ("ASBA"). Applications for 78767 Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The application for 5 cases having 12,118 Additional Rights Equity Shares were rejected where the shareholder had partly renounced and applied for Additional Rights Equity Shares. The said Applications for 12,118 Additional Rights Equity Shares have not been considered for Allotment. The total number of valid applications received were 296 for 21,24,053 Equity Shares, which aggregates to 142.79% of the total number of Equity Shares allotted under the Issue. In accordance with the LOF the basis of allotment finalized on Tuesday, September 23, 2025 in consultation with the Company, the Registrar to the Issue and National Stock Exchange of India Limited, the Stock Exchange for the Issue. The Company has on Tuesday, September 23, 2025 allotted 14,87,443 Rights Equity Shares to the successful applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. We hereby confirm that all the valid applications have been considered for Allotment.
In accordance with Regulation 86 of SEBI ICDR Regulations, 2018 Our Company is required to achieve minimum subscription for the Rights Issue.

1.Information regarding total number of Applications received:

Category	Applications Received		Equity Shares Applied for			Equity Shares allotted		
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%
Eligible Equity Shareholders	503	95.09 %	9,33,833	7,56,40,473	42.39 %	3,66,196	2,96,61,876	24.62%
Renouncees	22	4.16 %	1,96,295	1,58,99,895	8.91 %	49,551	40,13,631	3.33 %
Specific Investor*	4	0.76 %	10,72,692	8,68,88,052	48.70 %	10,71,696	8,68,07,376	72.05 %
Total	**529**	**100.00%**	**22,02,820**	**17,84,28,420**	**100.00 %**	**14,87,443**	**12,04,82,883**	**100.00 %**

*** In terms of Reg 77B (1) (a)** of SEBI ICDR Regulations, 2018, the Company had published a public advertisement in the newspaper specifying the name of Specific Investor,
The details of Specific Investor from whom applications were received are as mentioned below:

Sr. No	Name of Specific Investor	Equity Shares allotted	Value (Rs)
1	AMRIT KAAL OPPORTUNITIES FUND	3,09,922	2,51,03,682
2	Mr. ASHSISH VASANI	61,918	50,15,358
3	Mr. GUARANG VASANI ON BEHALF OF M/S. STELLAR GROWTH ADVISORS	6,36,693	5,15,72,133
4	Ms. VRANDA RATHI	63,163	51,16,203

2.Basis of Allotment

Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)
	Number	Number	Number	Number
Shareholders	270	2,13,974	1,52,222	3,66,196
Renouncees	22	49,551	0	49,551
Specific Investor	4	10,71,613	83	10,71,696
Total	**296**	**13,35,138**	**1,52,305**	**14,87,443**

Intimations for Allotment/refund/rejection cases: The dispatch of allotment advice cum refund intimation, as applicable, to the investors has been completed on September 24, 2025.The instructions to SCSBs for unblocking funds in case of ASBA Applications were given on September 23, 2025. The Listing application has been filed with NSE on September 24, 2025 and subsequently the Listing approval will be received on or about September 25, 2025. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of allottees will be completed on or about September 25, 2025. No Physical shares were tendered in the Rights Issue. Pursuant to Listing and Trading Approvals granted by National Stock Exchange of India Limited, the Rights Equity Shares Allotted in the issue is expected to commence the trading on National Stock Exchange of India Limited on or about September 26, 2025 and shall be traded under the same ISIN: INE0FMW01018 as the existing Equity Shares. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has be sent to NSDL & CDSL on or about Wednesday, September 24, 2025.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM

DISCLAIMER CLAUSE OF NSE (STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not, in any way, be deemed or construed that the Letter of Offer has been cleared or approved by the NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer in the full text of the "Disclaimer clause of NSE" on page 59 of the Letter of Offer.

Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

REGISTRAR TO THE ISSUE	Company Secretary
Bigshare Services Private Limited **1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400 059, Maharashtra, India.** **Tel No.: +91 22 6263 8200** **Email: rightsissue@bigshareonline.com** **Website:** www.bigshareonline.com **Investor Grievance Email:** investor@bigshareonline.com **Contact Person: Mr. Suraj Gupta** **SEBI Registration No.: INR000001385** **Validity of Registration: Permanent**	**Toral Jailesh Bhadra** A1 A2/B1 B2, Navkala Bharti Bldg , Plot No16 Prabhat Colony, opp near Santacruz Bus depot Santacruz East, Mumbai City, Mumbai, Maharashtra, India, 400055. **Telephone:** +91 22 6288 1111 **Email**: contact@qmsmas.com **Website:** : www.qmsmas.com

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving folio details such as name, address of the Applicant contact numbers), e- mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process) ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as the-case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process).

THE LEVEL OF SUBSCRPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

FOR QMS MEDICAL ALLIED SERVIES Limited
Sd/-
Toral Jailesh Bhadra
Company Secretary & Compliance Officer

Date: September 24, 2025
Place: Mumbai

Disclaimer: The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. NSE at www.nseindia.com and the website of the Registrar to the issue at bigshareonline.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 22 of the Letter of Offer.

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

QMS MEDICAL ALLIED SERVICES LIMITED ("Company" or "Issuer") was incorporated as a private limited company under the Companies Act, 2013 in the name of QMS MEDICAL ALLIED SERVICES PRIVATE LIMITED at Mumbai vide Certificate of Incorporation dated September 14, 2017. Pursuant to conversion of our Company to a public limited company, our name was changed to QMS MEDICAL ALLIED SERVICES LIMITED and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC, Mumbai on November 16, 2020. For details, please refer to the section titled "General Information" beginning on page no. 35 of the Letter of Offer.

Registered Office: AT A1 A2/B1 B2, NAVKALA BHARTI BLDG PLOT NO16 PRABHAT COLONY OPP NEAR SANTACRUZ BUS DEPOT SANTACRUZ EAST, MUMBAI CITY, MUMBAI, MAHARASHTRA, INDIA, 400055
Tel: +91 22 6288 1111 ; Contact Person: Ms. Toral Jailesh Bhadra, Company Secretary and Compliance Officer ;,
E-mail: contact@qmsmas.com; Website: www.qmsmas.com ; Corporate Identification Number: L33309MH2017PLC299748

PROMOTER OF OUR COMPANY: MAHESH MAKHIJA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF QMS MEDICAL ALLIED SERVICES LIMITED (THE "COMPANY" OR "THE ISSUER" ONLY

ISSUE OF 14,87,500 EQUITY SHARES OF FACE VALUE OF Rs. 10.00/- (RIGHTS EQUITY SHARES) OF QMS MEDICAL ALLIED SERVICES LIMITED (THE COMPANY OR THE "ISSUER") FOR CASH AT A PRICE OF Rs. 81/- (RUPEES EIGHTY-ONE ONLY) PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF Rs. 71/- (RUPEES SEVENTY-ONE ONLY) PER RIGHTS EQUITY SHARE) („ISSUE PRICE) FOR AN AMOUNT TO Rs. 12,04,87,500/- (RUPEES TWELVE CRORE FOUR LAKH EIGHTY-SEVEN THOUSAND AND FIVE HUNDRED ONLY) ON A RIGHTS ISSUE BASIS TO THE ELIGIBLE SHAREHOLDERS IN THE RATIO OF ONE RIGHT SHARES FOR EVERY TWELVE EQUITY SHARES HELD BY SUCH ELIGIBLE SHAREHOLDERS AS ON THE RECORD DATE, SEPTEMBER 04, 2025 ("ISSUE").

BASIS OF ALLOTMENT

The Board of Directors of QMS MEDICAL ALLIED SERVICES LIMITED wishes to thank all its members and investors for the overwhelming response to the Company's Rights Issue of Equity Shares, which opened for subscription on Friday, September 12, 2025 and closed on Monday, September 22, 2025 and the last date for market renunciation of Rights Entitlements was on Wednesday, September 17, 2025. In Rights Issue we received total 529 Applications for 22,02,820 Equity Shares (includes 4 applications of 10,71,613 Equity shares by Specific Investor) through Application Supported by Blocked Amount ("ASBA"). Applications for 78767 Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The application for 5 cases having 12,118 Additional Rights Equity Shares were rejected where the shareholder had partly renounced and applied for Additional Rights Equity Shares. The said Applications for 12,118 Additional Rights Equity Shares have not been considered for Allotment. The total number of valid applications received were 296 for 21,24,053 Equity Shares, which aggregates to 142.79% of the total number of Equity Shares allotted under the Issue. In accordance with the LOF the basis of allotment finalized on Tuesday, September 23, 2025 in consultation with the Company, the Registrar to the Issue and National Stock Exchange of India Limited, the Stock Exchange for the Issue. The Company has on Tuesday, September 23, 2025 allotted 14,87,443 Rights Equity Shares to the successful applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. We hereby confirm that all the valid applications have been considered for Allotment.
In accordance with Regulation 86 of SEBI ICDR Regulations, 2018 Our Company is required to achieve minimum subscription for the Rights Issue.

1.Information regarding total number of Applications received:

Category	Applications Received		Equity Shares Applied for			Equity Shares allotted		
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%
Eligible Equity Shareholders	503	95.09 %	9,33,833	7,56,40,473	42.39 %	3,66,196	2,96,61,876	24.62 %
Renouncees	22	4.16 %	1,96,295	1,58,99,895	8.91 %	49,551	40,13,631	3.33 %
Specific Investor*	4	0.76 %	10,72,692	8,68,88,052	48.70 %	10,71,696	8,68,07,376	72.05 %
Total	**529**	**100.00%**	**22,02,820**	**17,84,28,420**	**100.00 %**	**14,87,443**	**12,04,82,883**	**100.00 %**

*** In terms of Reg 77B (1) (a)** of SEBI ICDR Regulations, 2018, the Company had published a public advertisement in the newspaper specifying the name of Specific Investor,
The details of Specific Investor from whom applications were received are as mentioned below:

Sr. No	Name of Specific Investor	Equity Shares allotted	Value (Rs)
1	AMRIT KAAL OPPORTUNITIES FUND	3,09,922	2,51,03,682
2	Mr. ASHSISH VASANI	61,918	50,15,358
3	Mr. GUARANG VASANI ON BEHALF OF M/S. STELLAR GROWTH ADVISORS	6,36,693	5,15,72,133
4	Ms. VRANDA RATHI	63,163	51,16,203

2.Basis of Allotment

Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)
	Number	Number	Number	Number
Shareholders	270	2,13,974	1,52,222	3,66,196
Renouncees	22	49,551	0	49,551
Specific Investor	4	10,71,613	83	10,71,696
Total	**296**	**13,35,138**	**1,52,305**	**14,87,443**

Intimations for Allotment/refund/rejection cases: The dispatch of allotment advice cum refund intimation, as applicable, to the investors has been completed on September 24, 2025.The instructions to SCSBs for unblocking funds in case of ASBA Applications were given on September 23, 2025. The Listing application has been filed with NSE on September 24, 2025 and subsequently the Listing approval will be received on or about September 25, 2025. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of allottees will be completed on or about September 25, 2025. No Physical shares were tendered in the Rights Issue. Pursuant to Listing and Trading Approvals granted by National Stock Exchange of India Limited, the Rights Equity Shares Allotted in the issue is expected to commence the trading on National Stock Exchange of India Limited on or about September 26, 2025 and shall be traded under the same ISIN: INE0FMW01018 as the existing Equity Shares. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has be sent to NSDL & CDSL on or about Wednesday, September 24, 2025.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM

DISCLAIMER CLAUSE OF NSE (STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not, in any way, be deemed or construed that the Letter of Offer has been cleared or approved by the NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer in the full text of the "Disclaimer clause of NSE" on page 59 of the Letter of Offer.

Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

REGISTRAR TO THE ISSUE	Company Secretary
Bigshare Services Private Limited 1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400 059, Maharashtra, India. Tel No.: +91 22 6263 8200 Email: rightsissue@bigshareonline.com Website: www.bigshareonline.com Investor Grievance Email: investor@bigshareonline.com Contact Person: Mr. Suraj Gupta SEBI Registration No.: INR000001385 Validity of Registration: Permanent	**Toral Jailesh Bhadra** A1 A2/B1 B2, Navkala Bharti Bldg , Plot No16 Prabhat Colony, opp near Santacruz Bus depot Santacruz East, Mumbai City, Mumbai, Maharashtra, India, 400055. **Telephone:** +91 22 6288 1111 **Email**: contact@qmsmas.com **Website:** : www.qmsmas.com

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving folio details such as name, address of the Applicant contact numbers), e- mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process) ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as the-case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process).

THE LEVEL OF SUBSCRPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

FOR QMS MEDICAL ALLIED SERVIES Limited
Sd/-
Toral Jailesh Bhadra
Company Secretary & Compliance Officer

Date: September 24, 2025
Place: Mumbai

Disclaimer: The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. NSE at www.nseindia.com and the website of the Registrar to the issue at bigshareonline.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 22 of the Letter of Offer.

(This is only an Advertisement for information purpose and not an offer document announcement. Not for publication, distribution or release directly or indirectly into the United States or otherwise outside India.
All capitalized terms used and not defined herein shall have the meaning assigned to them in Letter of Offer dated August 29, 2025 ("the Letter of Offer" or "LOF") filed with National Stock Exchange of India and the Securities and Exchange Board of India ("SEBI").

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

QMS MEDICAL ALLIED SERVICES LIMITED ("Company" or "Issuer") was incorporated as a private limited company under the Companies Act, 2013 in the name of QMS MEDICAL ALLIED SERVICES PRIVATE LIMITED at Mumbai vide Certificate of Incorporation dated September 14, 2017. Pursuant to conversion of our Company to a public limited company, our name was changed to QMS MEDICAL ALLIED SERVICES LIMITED and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC, Mumbai on November 16, 2020. For details, please refer to the section titled "General Information" beginning on page no. 35 of the Letter of Offer.

Registered Office: AT A1 A2/B1 B2, NAVKALA BHARTI BLDG PLOT NO16 PRABHAT COLONY OPP NEAR SANTACRUZ BUS DEPOT SANTACRUZ EAST, MUMBAI CITY, MUMBAI, MAHARASHTRA, INDIA, 400055
Tel: +91 22 6288 1111 ; Contact Person: Ms. Toral Jailesh Bhadra, Company Secretary and Compliance Officer ;,
E-mail: contact@qmsmas.com; Website: www.qmsmas.com ; Corporate Identification Number: L33309MH2017PLC299748

PROMOTER OF OUR COMPANY: MAHESH MAKHIJA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF QMS MEDICAL ALLIED SERVICES LIMITED (THE "COMPANY" OR "THE ISSUER" ONLY

ISSUE OF 14,87,500 EQUITY SHARES OF FACE VALUE OF Rs. 10.00/- (RIGHTS EQUITY SHARES) OF QMS MEDICAL ALLIED SERVICES LIMITED (THE COMPANY OR THE "ISSUER") FOR CASH AT A PRICE OF Rs. 81/- (RUPEES EIGHTY-ONE ONLY) PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF Rs. 71/- (RUPEES SEVENTY-ONE ONLY) PER RIGHTS EQUITY SHARE) („ISSUE PRICE) FOR AN AMOUNT TO Rs. 12,04,87,500/- (RUPEES TWELVE CRORE FOUR LAKH EIGHTY-SEVEN THOUSAND AND FIVE HUNDRED ONLY) ON A RIGHTS ISSUE BASIS TO THE ELIGIBLE SHAREHOLDERS IN THE RATIO OF ONE RIGHT SHARES FOR EVERY TWELVE EQUITY SHARES HELD BY SUCH ELIGIBLE SHAREHOLDERS AS ON THE RECORD DATE, SEPTEMBER 04, 2025 ("ISSUE").

BASIS OF ALLOTMENT

The Board of Directors of QMS MEDICAL ALLIED SERVICES LIMITED wishes to thank all its members and investors for the overwhelming response to the Company's Rights Issue of Equity Shares, which opened for subscription on Friday, September 12, 2025 and closed on Monday, September 22, 2025 and the last date for market renunciation of Rights Entitlements was on Wednesday, September 17, 2025. In Rights Issue we received total 529 Applications for 22,02,820 Equity Shares (includes 4 applications of 10,71,613 Equity shares by Specific Investor) through Application Supported by Blocked Amount ("ASBA"). Applications for 78767 Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The application for 5 cases having 12,118 Additional Rights Equity Shares were rejected where the shareholder had partly renounced and applied for Additional Rights Equity Shares. The said Applications for 12,118 Additional Rights Equity Shares have not been considered for Allotment. The total number of valid applications received were 296 for 21,24,053 Equity Shares, which aggregates to 142.79% of the total number of Equity Shares allotted under the Issue. In accordance with the LOF the basis of allotment finalized on Tuesday, September 23, 2025 in consultation with the Company, the Registrar to the Issue and National Stock Exchange of India Limited, the Stock Exchange for the Issue. The Company has on Tuesday, September 23, 2025 allotted 14,87,443 Rights Equity Shares to the successful applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. We hereby confirm that all the valid applications have been considered for Allotment.
In accordance with Regulation 86 of SEBI ICDR Regulations, 2018 Our Company is required to achieve minimum subscription for the Rights Issue.

1.Information regarding total number of Applications received:

Category	Applications Received		Equity Shares Applied for			Equity Shares allotted		
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%
Eligible Equity Shareholders	503	95.09 %	9,33,833	7,56,40,473	42.39 %	3,66,196	2,96,61,876	24.62%
Renouncees	22	4.16 %	1,96,295	1,58,99,895	8.91 %	49,551	40,13,631	3.33 %
Specific Investor*	4	0.76 %	10,72,692	8,68,88,052	48.70 %	10,71,696	8,68,07,376	72.05 %
Total	**529**	**100.00%**	**22,02,820**	**17,84,28,420**	**100.00 %**	**14,87,443**	**12,04,82,883**	**100.00 %**

*** In terms of Reg 77B (1) (a)** of SEBI ICDR Regulations, 2018, the Company had published a public advertisement in the newspaper specifying the name of Specific Investor,
The details of Specific Investor from whom applications were received are as mentioned below:

Sr. No	Name of Specific Investor	Equity Shares allotted	Value (Rs)
1	AMRIT KAAL OPPORTUNITIES FUND	3,09,922	2,51,03,682
2	Mr. ASHSISH VASANI	61,918	50,15,358
3	Mr. GUARANG VASANI ON BEHALF OF M/S. STELLAR GROWTH ADVISORS	6,36,693	5,15,72,133
4	Ms. VRANDA RATHI	63,163	51,16,203

2.Basis of Allotment

Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)
	Number	Number	Number	Number
Shareholders	270	2,13,974	1,52,222	3,66,196
Renouncees	22	49,551	0	49,551
Specific Investor	4	10,71,613	83	10,71,696
Total	**296**	**13,35,138**	**1,52,305**	**14,87,443**

Intimations for Allotment/refund/rejection cases: The dispatch of allotment advice cum refund intimation, as applicable, to the investors has been completed on September 24, 2025.The instructions to SCSBs for unblocking funds in case of ASBA Applications were given on September 23, 2025. The Listing application has been filed with NSE on September 24, 2025 and subsequently the Listing approval will be received on or about September 25, 2025. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of allottees will be completed on or about September 25, 2025. No Physical shares were tendered in the Rights Issue. Pursuant to Listing and Trading Approvals granted by National Stock Exchange of India Limited, the Rights Equity Shares Allotted in the issue is expected to commence the trading on National Stock Exchange of India Limited on or about September 26, 2025 and shall be traded under the same ISIN: INE0FMW01018 as the existing Equity Shares. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has be sent to NSDL & CDSL on or about Wednesday, September 24, 2025.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM

DISCLAIMER CLAUSE OF NSE (STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not, in any way, be deemed or construed that the Letter of Offer has been cleared or approved by the NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer in the full text of the "Disclaimer clause of NSE" on page 59 of the Letter of Offer.

Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

REGISTRAR TO THE ISSUE	Company Secretary
Bigshare Services Private Limited **1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400 059, Maharashtra, India.** **Tel No.:** +91 22 6263 8200 **Email:** rightsissue@bigshareonline.com **Website:** www.bigshareonline.com **Investor Grievance Email:** investor@bigshareonline.com **Contact Person:** Mr. Suraj Gupta **SEBI Registration No.:** INR000001385 **Validity of Registration:** Permanent	**Toral Jailesh Bhadra** A1 A2/B1 B2, Navkala Bharti Bldg , Plot No16 Prabhat Colony, opp near Santacruz Bus depot Santacruz East, Mumbai City, Mumbai, Maharashtra, India, 400055. **Telephone:** +91 22 6288 1111 **Email:** contact@qmsmas.com **Website:** : www.qmsmas.com

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving folio details such as name, address of the Applicant contact numbers), e- mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process) ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as the-case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process).

THE LEVEL OF SUBSCRPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

FOR QMS MEDICAL ALLIED SERVIES Limited
Sd/-
Toral Jailesh Bhadra
Company Secretary & Compliance Officer

Date: September 24, 2025
Place: Mumbai

Disclaimer: The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. NSE at www.nseindia.com and the website of the Registrar to the issue at bigshareonline.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 22 of the Letter of Offer.

(This is only an Advertisement for information purpose and not an offer document announcement. Not for publication, distribution or release directly or indirectly into the United States or otherwise outside India.
All capitalized terms used and not defined herein shall have the meaning assigned to them in Letter of Offer dated August 29, 2025 ("the Letter of Offer" or "LOF") filed with National Stock Exchange of India and the Securities and Exchange Board of India ("SEBI").

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

QMS MEDICAL ALLIED SERVICES LIMITED ("Company" or "Issuer") was incorporated as a private limited company under the Companies Act, 2013 in the name of QMS MEDICAL ALLIED SERVICES PRIVATE LIMITED at Mumbai vide Certificate of Incorporation dated September 14, 2017. Pursuant to conversion of our Company to a public limited company, our name was changed to QMS MEDICAL ALLIED SERVICES LIMITED and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC, Mumbai on November 16, 2020. For details, please refer to the section titled "General Information" beginning on page no. 35 of the Letter of Offer.

Registered Office: AT A1 A2/B1 B2, NAVKALA BHARTI BLDG PLOT NO16 PRABHAT COLONY OPP NEAR SANTACRUZ BUS DEPOT SANTACRUZ EAST, MUMBAI CITY, MUMBAI, MAHARASHTRA, INDIA, 400055
Tel: +91 22 6288 1111 ; Contact Person: Ms. Toral Jailesh Bhadra, Company Secretary and Compliance Officer ;,
E-mail: contact@qmsmas.com; Website: www.qmsmas.com ; Corporate Identification Number: L33309MH2017PLC299748

PROMOTER OF OUR COMPANY: MAHESH MAKHIJA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF QMS MEDICAL ALLIED SERVICES LIMITED (THE "COMPANY" OR "THE ISSUER" ONLY

ISSUE OF 14,87,500 EQUITY SHARES OF FACE VALUE OF Rs. 10.00/- (RIGHTS EQUITY SHARES) OF QMS MEDICAL ALLIED SERVICES LIMITED (THE COMPANY OR THE "ISSUER") FOR CASH AT A PRICE OF Rs. 81/- (RUPEES EIGHTY-ONE ONLY) PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF Rs. 71/- (RUPEES SEVENTY-ONE ONLY) PER RIGHTS EQUITY SHARE) („ISSUE PRICE) FOR AN AMOUNT TO Rs. 12,04,87,500/- (RUPEES TWELVE CRORE FOUR LAKH EIGHTY-SEVEN THOUSAND AND FIVE HUNDRED ONLY) ON A RIGHTS ISSUE BASIS TO THE ELIGIBLE SHAREHOLDERS IN THE RATIO OF ONE RIGHT SHARES FOR EVERY TWELVE EQUITY SHARES HELD BY SUCH ELIGIBLE SHAREHOLDERS AS ON THE RECORD DATE, SEPTEMBER 04, 2025 ("ISSUE").

BASIS OF ALLOTMENT

The Board of Directors of QMS MEDICAL ALLIED SERVICES LIMITED wishes to thank all its members and investors for the overwhelming response to the Company's Rights Issue of Equity Shares, which opened for subscription on Friday, September 12, 2025 and closed on Monday, September 22, 2025 and the last date for market renunciation of Rights Entitlements was on Wednesday, September 17, 2025. In Rights Issue we received total 529 Applications for 22,02,820 Equity Shares (includes 4 applications of 10,71,613 Equity shares by Specific Investor) through Application Supported by Blocked Amount ("ASBA"). Applications for 78767 Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The application for 5 cases having 12,118 Additional Rights Equity Shares were rejected where the shareholder had partly renounced and applied for Additional Rights Equity Shares. The said Applications for 12,118 Additional Rights Equity Shares have not been considered for Allotment. The total number of valid applications received were 296 for 21,24,053 Equity Shares, which aggregates to 142.79% of the total number of Equity Shares allotted under the Issue. In accordance with the LOF the basis of allotment finalized on Tuesday, September 23, 2025 in consultation with the Company, the Registrar to the Issue and National Stock Exchange of India Limited, the Stock Exchange for the Issue. The Company has on Tuesday, September 23, 2025 allotted 14,87,443 Rights Equity Shares to the successful applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. We hereby confirm that all the valid applications have been considered for Allotment.
In accordance with Regulation 86 of SEBI ICDR Regulations, 2018 Our Company is required to achieve minimum subscription for the Rights Issue.

1.Information regarding total number of Applications received:

Category	Applications Received		Equity Shares Applied for			Equity Shares allotted		
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%
Eligible Equity Shareholders	503	95.09 %	9,33,833	7,56,40,473	42.39 %	3,66,196	2,96,61,876	24.62%
Renouncees	22	4.16 %	1,96,295	1,58,99,895	8.91 %	49,551	40,13,631	3.33 %
Specific Investor*	4	0.76 %	10,72,692	8,68,88,052	48.70 %	10,71,696	8,68,07,376	72.05 %
Total	**529**	**100.00%**	**22,02,820**	**17,84,28,420**	**100.00 %**	**14,87,443**	**12,04,82,883**	**100.00 %**

*** In terms of Reg 77B (1) (a)** of SEBI ICDR Regulations, 2018, the Company had published a public advertisement in the newspaper specifying the name of Specific Investor,
The details of Specific Investor from whom applications were received are as mentioned below:

Sr. No	Name of Specific Investor	Equity Shares allotted	Value (Rs)
1	AMRIT KAAL OPPORTUNITIES FUND	3,09,922	2,51,03,682
2	Mr. ASHSISH VASANI	61,918	50,15,358
3	Mr. GUARANG VASANI ON BEHALF OF M/S. STELLAR GROWTH ADVISORS	6,36,693	5,15,72,133
4	Ms. VRANDA RATHI	63,163	51,16,203

2.Basis of Allotment

Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)
	Number	Number	Number	Number
Shareholders	270	2,13,974	1,52,222	3,66,196
Renouncees	22	49,551	0	49,551
Specific Investor	4	10,71,613	83	10,71,696
Total	**296**	**13,35,138**	**1,52,305**	**14,87,443**

Intimations for Allotment/refund/rejection cases: The dispatch of allotment advice cum refund intimation, as applicable, to the investors has been completed on September 24, 2025.The instructions to SCSBs for unblocking funds in case of ASBA Applications were given on September 23, 2025. The Listing application has been filed with NSE on September 24, 2025 and subsequently the Listing approval will be received on or about September 25, 2025. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of allottees will be completed on or about September 25, 2025. No Physical shares were tendered in the Rights Issue. Pursuant to Listing and Trading Approvals granted by National Stock Exchange of India Limited, the Rights Equity Shares Allotted in the issue is expected to commence the trading on National Stock Exchange of India Limited on or about September 26, 2025 and shall be traded under the same ISIN: INE0FMW01018 as the existing Equity Shares. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has be sent to NSDL & CDSL on or about Wednesday, September 24, 2025.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM

DISCLAIMER CLAUSE OF NSE (STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not, in any way, be deemed or construed that the Letter of Offer has been cleared or approved by the NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer in the full text of the "Disclaimer clause of NSE" on page 59 of the Letter of Offer.
Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

REGISTRAR TO THE ISSUE	Company Secretary
Bigshare Services Private Limited **1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400 059, Maharashtra, India.** **Tel No.: +91 22 6263 8200** **Email: rightsissue@bigshareonline.com** **Website:** www.bigshareonline.com **Investor Grievance Email:** investor@bigshareonline.com **Contact Person: Mr. Suraj Gupta** **SEBI Registration No.: INR000001385** **Validity of Registration: Permanent**	**Toral Jailesh Bhadra** A1 A2/B1 B2, Navkala Bharti Bldg , Plot No16 Prabhat Colony, opp near Santacruz Bus depot Santacruz East, Mumbai City, Mumbai, Maharashtra, India, 400055. **Telephone:** +91 22 6288 1111 **Email**: contact@qmsmas.com **Website:** : www.qmsmas.com

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving folio details such as name, address of the Applicant contact numbers), e- mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process) ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as the-case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process).

THE LEVEL OF SUBSCRPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

FOR QMS MEDICAL ALLIED SERVIES Limited
Sd/-
Toral Jailesh Bhadra
Company Secretary & Compliance Officer

Date: September 24, 2025
Place: Mumbai

Disclaimer: The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. NSE at www.nseindia.com and the website of the Registrar to the issue at bigshareonline.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 22 of the Letter of Offer.

(This is only an Advertisement for information purpose and not an offer document announcement. Not for publication, distribution or release directly or indirectly into the United States or otherwise outside India.
All capitalized terms used and not defined herein shall have the meaning assigned to them in Letter of Offer dated August 29, 2025 ("the Letter of Offer" or "LOF") filed with National Stock Exchange of India and the Securities and Exchange Board of India ("SEBI").

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

QMS MEDICAL ALLIED SERVICES LIMITED ("Company" or "Issuer") was incorporated as a private limited company under the Companies Act, 2013 in the name of QMS MEDICAL ALLIED SERVICES PRIVATE LIMITED at Mumbai vide Certificate of Incorporation dated September 14, 2017. Pursuant to conversion of our Company to a public limited company, our name was changed to QMS MEDICAL ALLIED SERVICES LIMITED and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC, Mumbai on November 16, 2020. For details, please refer to the section titled "General Information" beginning on page no. 35 of the Letter of Offer.

Registered Office: AT A1 A2/B1 B2, NAVKALA BHARTI BLDG PLOT NO16 PRABHAT COLONY OPP NEAR SANTACRUZ BUS DEPOT SANTACRUZ EAST, MUMBAI CITY, MUMBAI, MAHARASHTRA, INDIA, 400055
Tel: +91 22 6288 1111 ; Contact Person: Ms. Toral Jailesh Bhadra, Company Secretary and Compliance Officer ;,
E-mail: contact@qmsmas.com; Website: www.qmsmas.com ; Corporate Identification Number: L33309MH2017PLC299748

PROMOTER OF OUR COMPANY: MAHESH MAKHIJA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF QMS MEDICAL ALLIED SERVICES LIMITED (THE "COMPANY" OR "THE ISSUER" ONLY

ISSUE OF 14,87,500 EQUITY SHARES OF FACE VALUE OF Rs. 10.00/- (RIGHTS EQUITY SHARES) OF QMS MEDICAL ALLIED SERVICES LIMITED (THE COMPANY OR THE "ISSUER") FOR CASH AT A PRICE OF Rs. 81/- (RUPEES EIGHTY-ONE ONLY) PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF Rs. 71/- (RUPEES SEVENTY-ONE ONLY) PER RIGHTS EQUITY SHARE) („ISSUE PRICE) FOR AN AMOUNT TO Rs. 12,04,87,500/- (RUPEES TWELVE CRORE FOUR LAKH EIGHTY-SEVEN THOUSAND AND FIVE HUNDRED ONLY) ON A RIGHTS ISSUE BASIS TO THE ELIGIBLE SHAREHOLDERS IN THE RATIO OF ONE RIGHT SHARES FOR EVERY TWELVE EQUITY SHARES HELD BY SUCH ELIGIBLE SHAREHOLDERS AS ON THE RECORD DATE, SEPTEMBER 04, 2025 ("ISSUE").

BASIS OF ALLOTMENT

The Board of Directors of QMS MEDICAL ALLIED SERVICES LIMITED wishes to thank all its members and investors for the overwhelming response to the Company's Rights Issue of Equity Shares, which opened for subscription on Friday, September 12, 2025 and closed on Monday, September 22, 2025 and the last date for market renunciation of Rights Entitlements was on Wednesday, September 17, 2025. In Rights Issue we received total 529 Applications for 22,02,820 Equity Shares (includes 4 applications of 10,71,613 Equity shares by Specific Investor) through Application Supported by Blocked Amount ("ASBA"). Applications for 78767 Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The application for 5 cases having 12,118 Additional Rights Equity Shares were rejected where the shareholder had partly renounced and applied for Additional Rights Equity Shares. The said Applications for 12,118 Additional Rights Equity Shares have not been considered for Allotment. The total number of valid applications received were 296 for 21,24,053 Equity Shares, which aggregates to 142.79% of the total number of Equity Shares allotted under the Issue. In accordance with the LOF the basis of allotment finalized on Tuesday, September 23, 2025 in consultation with the Company, the Registrar to the Issue and National Stock Exchange of India Limited, the Stock Exchange for the Issue. The Company has on Tuesday, September 23, 2025 allotted 14,87,443 Rights Equity Shares to the successful applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. We hereby confirm that all the valid applications have been considered for Allotment.
In accordance with Regulation 86 of SEBI ICDR Regulations, 2018 Our Company is required to achieve minimum subscription for the Rights Issue.

1.Information regarding total number of Applications received:

Category	Applications Received		Equity Shares Applied for			Equity Shares allotted		
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%
Eligible Equity Shareholders	503	95.09 %	9,33,833	7,56,40,473	42.39 %	3,66,196	2,96,61,876	24.62 %
Renouncees	22	4.16 %	1,96,295	1,58,99,895	8.91 %	49,551	40,13,631	3.33 %
Specific Investor*	4	0.76 %	10,72,692	8,68,88,052	48.70 %	10,71,696	8,68,07,376	72.05 %
Total	**529**	**100.00%**	**22,02,820**	**17,84,28,420**	**100.00 %**	**14,87,443**	**12,04,82,883**	**100.00 %**

*** In terms of Reg 77B (1) (a)** of SEBI ICDR Regulations, 2018, the Company had published a public advertisement in the newspaper specifying the name of Specific Investor,
The details of Specific Investor from whom applications were received are as mentioned below:

Sr. No	Name of Specific Investor	Equity Shares allotted	Value (Rs)
1	AMRIT KAAL OPPORTUNITIES FUND	3,09,922	2,51,03,682
2	Mr. ASHSISH VASANI	61,918	50,15,358
3	Mr. GUARANG VASANI ON BEHALF OF M/S. STELLAR GROWTH ADVISORS	6,36,693	5,15,72,133
4	Ms. VRANDA RATHI	63,163	51,16,203

2.Basis of Allotment

Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)
	Number	Number	Number	Number
Shareholders	270	2,13,974	1,52,222	3,66,196
Renouncees	22	49,551	0	49,551
Specific Investor	4	10,71,613	83	10,71,696
Total	**296**	**13,35,138**	**1,52,305**	**14,87,443**

Intimations for Allotment/refund/rejection cases: The dispatch of allotment advice cum refund intimation, as applicable, to the investors has been completed on September 24, 2025.The instructions to SCSBs for unblocking funds in case of ASBA Applications were given on September 23, 2025. The Listing application has been filed with NSE on September 24, 2025 and subsequently the Listing approval will be received on or about September 25, 2025. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of allottees will be completed on or about September 25, 2025. No Physical shares were tendered in the Rights Issue. Pursuant to Listing and Trading Approvals granted by National Stock Exchange of India Limited, the Rights Equity Shares Allotted in the issue is expected to commence the trading on National Stock Exchange of India Limited on or about September 26, 2025 and shall be traded under the same ISIN: INE0FMW01018 as the existing Equity Shares. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has be sent to NSDL & CDSL on or about Wednesday, September 24, 2025.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM

DISCLAIMER CLAUSE OF NSE (STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not, in any way, be deemed or construed that the Letter of Offer has been cleared or approved by the NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer in the full text of the "Disclaimer clause of NSE" on page 59 of the Letter of Offer.
Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

REGISTRAR TO THE ISSUE	Company Secretary
Bigshare Services Private Limited **1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400 059, Maharashtra, India.** **Tel No.: +91 22 6263 8200** **Email: rightsissue@bigshareonline.com** **Website:** www.bigshareonline.com **Investor Grievance Email:** investor@bigshareonline.com **Contact Person: Mr. Suraj Gupta** **SEBI Registration No.: INR000001385** **Validity of Registration: Permanent**	**Toral Jailesh Bhadra** A1 A2/B1 B2, Navkala Bharti Bldg , Plot No16 Prabhat Colony, opp near Santacruz Bus depot Santacruz East, Mumbai City, Mumbai, Maharashtra, India, 400055. **Telephone:** +91 22 6288 1111 **Email**: contact@qmsmas.com **Website:** : www.qmsmas.com

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving folio details such as name, address of the Applicant contact numbers), e- mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process) ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as the-case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process).

THE LEVEL OF SUBSCRPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

FOR QMS MEDICAL ALLIED SERVIES Limited
Sd/-
Toral Jailesh Bhadra
Company Secretary & Compliance Officer

Date: September 24, 2025
Place: Mumbai

Disclaimer: The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. NSE at www.nseindia.com and the website of the Registrar to the issue at bigshareonline.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 22 of the Letter of Offer.

(This is only an Advertisement for information purpose and not an offer document announcement. Not for publication, distribution or release directly or indirectly into the United States or otherwise outside India.
All capitalized terms used and not defined herein shall have the meaning assigned to them in Letter of Offer dated August 29, 2025 ("the Letter of Offer" or "LOF") filed with National Stock Exchange of India and the Securities and Exchange Board of India ("SEBI").

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

QMS MEDICAL ALLIED SERVICES LIMITED ("Company" or "Issuer") was incorporated as a private limited company under the Companies Act, 2013 in the name of QMS MEDICAL ALLIED SERVICES PRIVATE LIMITED at Mumbai vide Certificate of Incorporation dated September 14, 2017. Pursuant to conversion of our Company to a public limited company, our name was changed to QMS MEDICAL ALLIED SERVICES LIMITED and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC, Mumbai on November 16, 2020. For details, please refer to the section titled "General Information" beginning on page no. 35 of the Letter of Offer.

Registered Office: AT A1 A2/B1 B2, NAVKALA BHARTI BLDG PLOT NO16 PRABHAT COLONY OPP NEAR SANTACRUZ BUS DEPOT SANTACRUZ EAST, MUMBAI CITY, MUMBAI, MAHARASHTRA, INDIA, 400055
Tel: +91 22 6288 1111 ; Contact Person: Ms. Toral Jailesh Bhadra, Company Secretary and Compliance Officer ;,
E-mail: contact@qmsmas.com; Website: www.qmsmas.com ; Corporate Identification Number: L33309MH2017PLC299748

PROMOTER OF OUR COMPANY: MAHESH MAKHIJA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF QMS MEDICAL ALLIED SERVICES LIMITED (THE "COMPANY" OR "THE ISSUER" ONLY

ISSUE OF 14,87,500 EQUITY SHARES OF FACE VALUE OF Rs. 10.00/- (RIGHTS EQUITY SHARES) OF QMS MEDICAL ALLIED SERVICES LIMITED (THE COMPANY OR THE "ISSUER") FOR CASH AT A PRICE OF Rs. 81/- (RUPEES EIGHTY-ONE ONLY) PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF Rs. 71/- (RUPEES SEVENTY-ONE ONLY) PER RIGHTS EQUITY SHARE) („ISSUE PRICE) FOR AN AMOUNT TO Rs. 12,04,87,500/- (RUPEES TWELVE CRORE FOUR LAKH EIGHTY-SEVEN THOUSAND AND FIVE HUNDRED ONLY) ON A RIGHTS ISSUE BASIS TO THE ELIGIBLE SHAREHOLDERS IN THE RATIO OF ONE RIGHT SHARES FOR EVERY TWELVE EQUITY SHARES HELD BY SUCH ELIGIBLE SHAREHOLDERS AS ON THE RECORD DATE, SEPTEMBER 04, 2025 ("ISSUE").

BASIS OF ALLOTMENT

The Board of Directors of QMS MEDICAL ALLIED SERVICES LIMITED wishes to thank all its members and investors for the overwhelming response to the Company's Rights Issue of Equity Shares, which opened for subscription on Friday, September 12, 2025 and closed on Monday, September 22, 2025 and the last date for market renunciation of Rights Entitlements was on Wednesday, September 17, 2025. In Rights Issue we received total 529 Applications for 22,02,820 Equity Shares (includes 4 applications of 10,71,613 Equity shares by Specific Investor) through Application Supported by Blocked Amount ("ASBA"). Applications for 78767 Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The application for 5 cases having 12,118 Additional Rights Equity Shares were rejected where the shareholder had partly renounced and applied for Additional Rights Equity Shares. The said Applications for 12,118 Additional Rights Equity Shares have not been considered for Allotment. The total number of valid applications received were 296 for 21,24,053 Equity Shares, which aggregates to 142.79% of the total number of Equity Shares allotted under the Issue. In accordance with the LOF the basis of allotment finalized on Tuesday, September 23, 2025 in consultation with the Company, the Registrar to the Issue and National Stock Exchange of India Limited, the Stock Exchange for the Issue. The Company has on Tuesday, September 23, 2025 allotted 14,87,443 Rights Equity Shares to the successful applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. We hereby confirm that all the valid applications have been considered for Allotment.
In accordance with Regulation 86 of SEBI ICDR Regulations, 2018 Our Company is required to achieve minimum subscription for the Rights Issue.

1.Information regarding total number of Applications received:

Category	Applications Received		Equity Shares Applied for			Equity Shares allotted		
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%
Eligible Equity Shareholders	503	95.09 %	9,33,833	7,56,40,473	42.39 %	3,66,196	2,96,61,876	24.62%
Renouncees	22	4.16 %	1,96,295	1,58,99,895	8.91 %	49,551	40,13,631	3.33 %
Specific Investor*	4	0.76 %	10,72,692	8,68,88,052	48.70 %	10,71,696	8,68,07,376	72.05 %
Total	**529**	**100.00%**	**22,02,820**	**17,84,28,420**	**100.00 %**	**14,87,443**	**12,04,82,883**	**100.00 %**

*** In terms of Reg 77B (1) (a)** of SEBI ICDR Regulations, 2018, the Company had published a public advertisement in the newspaper specifying the name of Specific Investor,
The details of Specific Investor from whom applications were received are as mentioned below:

Sr. No	Name of Specific Investor	Equity Shares allotted	Value (Rs)
1	AMRIT KAAL OPPORTUNITIES FUND	3,09,922	2,51,03,682
2	Mr. ASHSISH VASANI	61,918	50,15,358
3	Mr. GUARANG VASANI ON BEHALF OF M/S. STELLAR GROWTH ADVISORS	6,36,693	5,15,72,133
4	Ms. VRANDA RATHI	63,163	51,16,203

2.Basis of Allotment

Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)
	Number	Number	Number	Number
Shareholders	270	2,13,974	1,52,222	3,66,196
Renouncees	22	49,551	0	49,551
Specific Investor	4	10,71,613	83	10,71,696
Total	**296**	**13,35,138**	**1,52,305**	**14,87,443**

Intimations for Allotment/refund/rejection cases: The dispatch of allotment advice cum refund intimation, as applicable, to the investors has been completed on September 24, 2025.The instructions to SCSBs for unblocking funds in case of ASBA Applications were given on September 23, 2025. The Listing application has been filed with NSE on September 24, 2025 and subsequently the Listing approval will be received on or about September 25, 2025. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of allottees will be completed on or about September 25, 2025. No Physical shares were tendered in the Rights Issue. Pursuant to Listing and Trading Approvals granted by National Stock Exchange of India Limited, the Rights Equity Shares Allotted in the issue is expected to commence the trading on National Stock Exchange of India Limited on or about September 26, 2025 and shall be traded under the same ISIN: INE0FMW01018 as the existing Equity Shares. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has be sent to NSDL & CDSL on or about Wednesday, September 24, 2025.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM

DISCLAIMER CLAUSE OF NSE (STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not, in any way, be deemed or construed that the Letter of Offer has been cleared or approved by the NSE, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer in the full text of the "Disclaimer clause of NSE" on page 59 of the Letter of Offer.
Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

REGISTRAR TO THE ISSUE	Company Secretary
Bigshare Services Private Limited **1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400 059, Maharashtra, India.** **Tel No.: +91 22 6263 8200** **Email: rightsissue@bigshareonline.com** **Website:** www.bigshareonline.com **Investor Grievance Email:** investor@bigshareonline.com **Contact Person: Mr. Suraj Gupta** **SEBI Registration No.: INR000001385** **Validity of Registration: Permanent**	**Toral Jailesh Bhadra** A1 A2/B1 B2, Navkala Bharti Bldg , Plot No16 Prabhat Colony, opp near Santacruz Bus depot Santacruz East, Mumbai City, Mumbai, Maharashtra, India, 400055. **Telephone:** +91 22 6288 1111 **Email**: contact@qmsmas.com **Website:** : www.qmsmas.com

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving folio details such as name, address of the Applicant contact numbers), e- mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process) ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as the-case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process).

THE LEVEL OF SUBSCRPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

FOR QMS MEDICAL ALLIED SERVIES Limited
Sd/-
Toral Jailesh Bhadra
Company Secretary & Compliance Officer

Date: September 24, 2025
Place: Mumbai

Disclaimer: The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. NSE at www.nseindia.com and the website of the Registrar to the issue at bigshareonline.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 22 of the Letter of Offer.